3,279 results on '"Alton A"'
Search Results
2. YOUR FIRST 30 DAYS AS AN HR LEADER: Attaining a leadership position in HR is an exciting--and often stressful--time. Planning for your success and demonstrating your worth early on can give you a good start
- Author
-
Alton, Liz
- Subjects
Employee performance ,Business ,Human resources and labor relations - Abstract
The first 30 days in a new HR leadership role are crucial to understanding your organization and establishing your place within it. You only get one chance to make a [...]
- Published
- 2024
3. Planning a Career in Business.
- Author
-
Finch, Alton V.
- Abstract
Recommends steps to take when planning a career in business. These include (l) learning more about job requirements, availability, and placement; (2) understanding changes occurring in the job market; and (3) learning how to get along with people and how to work under varying circumstances. (CT)
- Published
- 1981
4. Management, Functional Outcomes, and Quality of Life After Development of Pelvic Sepsis in Patients Undergoing Re-Do Ileal Pouch Anal Anastomosis
- Author
-
Feza H. Remzi, Alton G. Sutter, Joanna Esterow, Erman Aytac, Andre da Luz Moreira, Arman Erkan, Patricio B. Lynn, Hasan T. Kirat, Eren Esen, and Michael J. Grieco
- Subjects
medicine.medical_specialty ,business.industry ,Proctocolectomy, Restorative ,Gastroenterology ,Colonic Pouches ,Retrospective cohort study ,General Medicine ,medicine.disease ,Abscess ,Surgery ,Ileal Pouch Anal Anastomosis ,Sepsis ,Quality of life ,Quality of Life ,medicine ,Pelvic sepsis ,Humans ,Defecation ,Pouch ,business ,Retrospective Studies - Abstract
The data on management and outcomes of pelvic sepsis after re-do IPAA are scarce.The aim of this study is to report our management algorithm of pelvic sepsis in the setting of re-do IPAA and compare functional outcomes and quality of life after successful management of pelvic sepsis with a no sepsis control group.This is a retrospective cohort study.This investigation is based on a single academic practice group experience on re-do IPAA.Patients who underwent re-do IPAA for ileal pouch failure between September 2016 and September 2020 were included in the study.Management of pelvic sepsis was reported. Functional outcomes, restrictions, and quality-of-life scores were compared between the sepsis and no sepsis groups.One-hundred ten patients were included in our study, of whom 25 (22.7%) developed pelvic sepsis. Twenty-three patients presented with pelvic sepsis before ileostomy closure, and 2 patients presented with pelvic sepsis after ileostomy closure. There were 6 pouch failures in the study period due to pelvic sepsis. Our management was successful in 79% of the patients with median follow-up of 26 months. Treatments included interventional radiology abscess drainage (n = 7), IV antibiotics alone (n = 5), interventional radiology drainage and mushroom catheter placement (n = 1), mushroom catheter placement (n = 1), and endoluminal vacuum-assisted closure (n = 1). Average number of bowel movements, urgency, incontinence, pad use, and seepage were comparable between the pelvic sepsis and no pelvic sepsis groups ( p0.05). Lifestyle alterations, Cleveland Global Quality of Life scores, and happiness with the results of the surgery were similar ( p0.05).This study is limited by its low study power and limited follow-up time.Pelvic sepsis is common after re-do IPAA, and management varies according to the location and size of the abscess/sinus. If detected early, our management strategy was associated with high pouch salvage rates. See Video Abstract at http://links.lww.com/DCR/B823 .ANTECEDENTES:Los datos sobre el tratamiento y los resultados de la sepsis pélvica después de reconfección de anastomosis anal, de la bolsa ileal son escasos.OBJETIVO:El objetivo de este estudio es informar nuestro algoritmo de manejo de la sepsis pélvica en el contexto de reconfección de anastomosis anal de la bolsa ileal y comparar los resultados funcionales y la calidad de vida después del manejo exitoso de la sepsis pélvica con un grupo de control sin sepsis.DISEÑO:Este es un estudio de cohorte retrospectivo.AJUSTES:Esta investigación se basa en una experiencia de un solo grupo de práctica académica sobre reconfección de IPAA.PACIENTES:Se incluyeron en el estudio pacientes que se sometieron a una nueva anastomosis anal, del reservorio ileal por falla del reservorio ileal entre el 09/2016 y el 09/2020.PRINCIPALES MEDIDAS DE RESULTADO:Se informó el manejo de la sepsis pélvica. Los resultados funcionales, las restricciones y las puntuaciones de calidad de vida, se compararon entre los grupos con sepsis y sin sepsis.RESULTADOS:Se incluyeron 110 pacientes en nuestro estudio, de los cuales 25 (22,7) desarrollaron sepsis pélvica. Veintitrés pacientes presentaron sepsis pélvica antes del cierre de la ileostomía y 2 pacientes presentaron sepsis pélvica después del cierre de la ileostomía. Hubo 6 fallas de la bolsa en el período de estudio debido a sepsis pélvica. Nuestro manejo fue exitoso en el 79% de los pacientes con una mediana de seguimiento de 26 meses. Los tratamientos incluyeron drenaje de abscesos IR (n = 7), antibióticos intravenosos solos (n = 5), drenaje IR y colocación de catéter en forma de hongo (n = 1), colocación de catéter en forma de hongo (n = 1) y cierre endoluminal asistido por vacío (n = 1). El número promedio de evacuaciones intestinales, urgencia, incontinencia, uso de almohadillas y filtraciones fueron comparables entre los grupos con sepsis pélvica y sin sepsis pélvica ( p0,05). Las alteraciones del estilo de vida, las puntuaciones de la Calidad de vida global de Cleveland y la felicidad con los resultados de la cirugía fueron similares ( p0,05).LIMITACIONES:Este estudio está limitado por su bajo poder de estudio y su tiempo de seguimiento limitado.CONCLUSIONES:La sepsis pélvica es común después de la reconfección de anastomosis anal de la bolsa ileal y el manejo varía según la ubicación y el tamaño del absceso / seno. Si se detecta temprano, nuestra estrategia de manejo se asoció con altas tasas de recuperación de la bolsa. Consulte Video Resumen en http://links.lww.com/DCR/B823 . (Traducción-Dr. Mauricio Santamaria ).
- Published
- 2022
5. Open Ankle Fractures: What Predicts Infection? A Multicenter Study
- Author
-
Timothy Costales, Stephen Kottmeier, Andrew H. Schmidt, Michael J. Bosse, David S Sanders, Saam Morshed, Douglas S. Weinberg, Reza Firoozabadi, Ifeanyi Nzegwu, Megan R Dillman, Tigist Belaye, Paul Tornetta, Heather A. Vallier, Jerald R. Westberg, Timothy B. Alton, Rashad H. Usmani, C. D. Jones, Margaret E. Cooke, Daniel Leas, Robert V O'Toole, Max Coale, Brian Mullis, Michael T. Archdeacon, Rafael Kakazu, Kenneth A. Egol, Daniel S. Horwitz, David Teague, Harish Kempegowda, and Anna N. Miller
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Nonunion ,Acute infection ,Ankle Fractures ,Fracture Fixation, Internal ,Fractures, Open ,Young Adult ,Diabetes mellitus ,Humans ,Medicine ,Orthopedics and Sports Medicine ,Malunion ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Implant failure ,General Medicine ,Evidence-based medicine ,Middle Aged ,medicine.disease ,Surgery ,Tibial Fractures ,Treatment Outcome ,medicine.anatomical_structure ,Multi center study ,Female ,Ankle ,business - Abstract
OBJECTIVE To identify the patient, injury and treatment factors associated with an acute infection during the treatment of open ankle fractures in a large multi-center retrospective review. To evaluate the effect of infectious complications on the rates of nonunion, malunion, and loss of reduction. DESIGN Multi-center Retrospective Review. SETTING Sixteen Trauma Centers. PATIENTS One thousand and three consecutive skeletally mature patients (514 men and 489 women) with open ankle fractures. MAIN OUTCOME MEASURES Fracture-related infection (FRI) in open ankle fractures. RESULTS The charts of 1,003 consecutive patients were reviewed and 712 patients (357 women and 355 men) had at least 12 weeks of clinical follow-up. Their average age was 50 years (range 16-96), and average BMI was 31; they sustained OTA/AO types 44A (12%), 44B (58%), and 44C (30%) open ankle fractures. The rate FRI rate was 15%. A multivariable regression analysis identified male sex, diabetes, smoking, immunosuppressant use, time to wound closure, and wound location as independent risk factors for infection. There were 77 cases of malunion, nonunion, loss of reduction and/or implant failure; FRI was associated with higher rates of these complications (p=0.01). CONCLUSION Several patient, injury and surgical factors were associated with fracture-related infection in the treatment of open ankle fractures. LEVEL OF EVIDENCE Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
- Published
- 2022
6. Trends in and Maternal Outcomes of Delivery Hospitalizations of Patients With an Asthma Diagnosis
- Author
-
Alexander M Friedman, Timothy Wen, Jason D. Wright, Yongmei Huang, Jean Guglielminotti, Emily A DiMango, and Mary E. D'Alton
- Subjects
Gestational hypertension ,medicine.medical_specialty ,education.field_of_study ,Obstetrics ,business.industry ,Population ,Obstetrics and Gynecology ,Odds ratio ,medicine.disease ,Logistic regression ,Annual Percent Change ,Preeclampsia ,Gestational diabetes ,medicine ,education ,business ,Asthma - Abstract
OBJECTIVE To characterize asthma prevalence and outcomes during U.S. delivery hospitalizations. METHODS For this repeated cross-sectional analysis, deliveries to women aged 15-54 years with asthma were identified in the 2000-2018 National Inpatient Sample, which approximates a 20% stratified sample of all hospitalizations nationally. Temporal trends in asthma were analyzed using joinpoint regression to estimate the average annual percent change with 95% CIs. The association of asthma with other comorbid conditions was analyzed. The relationship between asthma and several adverse maternal outcomes was analyzed with unadjusted and adjusted logistic regression models, with unadjusted odds ratios and adjusted odds ratios (aORs) as measures of effect. Risk for and trends in a composite of rare, but severe, respiratory complications also were analyzed. RESULTS An estimated 73,109,790 delivery hospitalizations from 2000 to 2018 were included in the analysis, of which 2,221,644 (3.0%) had a diagnosis of asthma. (Unweighted, the study sample included 15,213,024 deliveries, of which 462,276 [3.0%] had a diagnosis of asthma.) Asthma diagnoses rose from 1.2% in 2000 to 5.3% in 2018, representing an average annual percent change of 8.3% (95% CI 7.4-9.2%). Asthma was more common among women with obesity and chronic hypertension. In adjusted analyses, asthma was associated with severe maternal morbidity (aOR 1.50, 95% CI 1.45-1.55), preeclampsia and gestational hypertension (aOR 1.29, 95% CI 1.26-1.30), postpartum hemorrhage (aOR 1.21, 95% CI 1.19-1.24), cesarean delivery (aOR 1.16, 95% CI 1.15-1.18), gestational diabetes (aOR 1.20, 95% CI 1.18-1.21), venous thromboembolism (aOR 1.79, 95% CI 1.65-1.95), and preterm delivery (aOR 1.27, 95% CI 1.25-1.29). From 2000 to 2018, severe respiratory complications decreased from 72 per 10,000 deliveries with asthma to 14 per 10,000 deliveries with asthma (average annual percent change -9.4%, 95% CI -13.3% to -5.3%). This decreasing risk was offset on a population level by an increase in the risk of asthma. CONCLUSION Asthma is increasing during deliveries, is associated with adverse maternal outcomes, and is associated with comorbid conditions. Severe respiratory complications are decreasing proportionately among deliveries with asthma, but are stable on a population basis.
- Published
- 2021
7. Exploring the Dynamics of Justification in the Wake of a Rumor Outbreak on Social Media
- Author
-
Alton Y. K. Chua, Snehasish Banerjee, and Anjan Pal
- Subjects
Knowledge management ,business.industry ,Dynamics (music) ,Management of Technology and Innovation ,Outbreak ,Social media ,Sociology ,Public relations ,Rumor ,Wake ,business ,Computer Science Applications ,Management Information Systems - Abstract
This paper explores the dynamics of justification in the wake of a rumor outbreak on social media. Specifically, it examines the extent to which the five types of justification—descriptive argumentation, presumptive argumentation, evidentialism, truth skepticism, and epistemological skepticism—manifested in different voices including pro-rumor, anti-rumor and doubts before and after fact-checking. Content analysis was employed on 1,911 tweets related to a rumor outbreak. Non-parametric cross-tabulation was used to uncover nuances in information sharing before and after fact-checking. Augmenting the literature which suggests the online community’s susceptibility to hoaxes, the paper offers a silver lining: Users are responsible enough to correct rumors during the later phase of a rumor lifecycle. This sense of public-spiritedness can be harnessed by knowledge management practitioners and public relations professionals for crowdsourced rumor refutation.
- Published
- 2021
8. Individualized risk trajectories for iron‐related adverse outcomes in repeat blood donors
- Author
-
David Scheinker, W. Alton Russell, and Brian Custer
- Subjects
medicine.medical_specialty ,biology ,Receiver operating characteristic ,Fingerstick ,Adverse outcomes ,business.industry ,Iron ,Immunology ,Blood Donors ,Hematology ,Iron deficiency ,medicine.disease ,Ferritin ,Hemoglobins ,Internal medicine ,Donation ,Ferritins ,Receptors, Transferrin ,biology.protein ,medicine ,Humans ,Immunology and Allergy ,Hemoglobin ,business ,Soluble transferrin receptor - Abstract
Despite a fingerstick hemoglobin requirement and 56-day minimum donation interval, repeat blood donation continues to cause and exacerbate iron deficiency.Using data from the REDS-II Donor Iron Status Evaluation study, we developed multiclass prediction models to estimate the competing risk of hemoglobin deferral and collecting blood from a donor with sufficient hemoglobin but low or absent underlying iron stores. We compared models developed with and without two biomarkers not routinely measured in most blood centers: ferritin and soluble transferrin receptor. We generated and analyzed "individual risk trajectories": estimates of how each donors' risk developed as a function of the time interval until their next donation attempt.With standard biomarkers, the top model had a multiclass area under the receiver operator characteristic curve (AUC) of 77.6% (95% CI [77.3%-77.8%]). With extra biomarkers, multiclass AUC increased to 82.8% (95% CI [82.5%-83.1%]). In the extra biomarkers model, ferritin was the single most important variable, followed by the donation interval. We identified three risk archetypes: "fast recoverers" (10% risk of any adverse outcome on post-donation day 56), "slow recoverers" (60% adverse outcome risk on day 56 that declines to35% by day 250), and "chronic high-risk" (85% risk of the adverse outcome on day 250).A longer donation interval reduced the estimated risk of iron-related adverse outcomesfor most donors, but risk remained high for some. Tailoring safeguards to individual risk estimates could reduce blood collections from donors with low or absent iron stores.
- Published
- 2021
9. Barriers and facilitators to accessing cancer care for people with significant mental health difficulties: A qualitative review and narrative synthesis
- Author
-
Paul D’Alton, Alanna Donnelly, Kelly E. Irwin, and Dorothy Leahy
- Subjects
Mental Health Services ,medicine.medical_specialty ,Health Personnel ,Social Stigma ,Population ,Psycho-oncology ,Experimental and Cognitive Psychology ,Neoplasms ,Cancer screening ,medicine ,Humans ,Narrative ,Healthcare Disparities ,education ,Qualitative Research ,education.field_of_study ,Mental health stigma ,business.industry ,Mental Disorders ,Cancer ,medicine.disease ,Mental health ,Psychiatry and Mental health ,Mental Health ,Oncology ,Family medicine ,business ,Qualitative research - Abstract
Objectives Inequities in cancer care contribute to higher rates of cancer mortality for individuals with significant mental health difficulties (SMHD) compared to the general population. The aim of the current systematic review was to identify, appraise and synthesise qualitative evidence of patient and clinician/system barriers and facilitators to cancer screening and treatment for individuals with SMHD. Methods We conducted a systematic search across three electronic databases in May 2020 and we carried out a second search across five electronic databases in January 2021. A narrative synthesis was conducted across eligible studies. Results We identified the same six studies from both searches, with 133 individuals with SMHD and experiences of cancer care and 102 healthcare professionals. Key barriers to cancer care were related to patients' uncontrolled psychiatric symptoms and the adverse impact of their symptoms on engaging with cancer care; clinician barrier-attitudes included stigmatising attitudes from clinicians and other staff towards individuals with SMHD and systems barrier-fragmentation included the fragmentation of mental health and cancer care delivery. Key patient facilitators to accessing cancer care and completing cancer treatment included being connected with mental health services and controlled psychiatric symptoms. Stronger collaboration among healthcare professionals working across different sectors in addition to the development of a patient navigator role were identified as key facilitators to enhance patient care. Conclusions Innovative approaches are needed to decrease mental health stigma, foster collaboration across disciplines, and facilitate the integration of timely mental health and cancer care for individuals with SMHD to address the mortality gap.
- Published
- 2021
10. Proliferation Activity in Canine Gastrointestinal Lymphoma
- Author
-
Iwan Burgener, Stefan Kummer, Klemens Alton, Birgitt Wolfesberger, Andrea Fuchs-Baumgartinger, Alexander Tichy, Sabine E. Hammer, Lea Liehmann, Stefanie Burger, Sabine Klinger, Barbara C. Rütgen, and Ingrid Walter
- Subjects
Pathology ,medicine.medical_specialty ,Mitotic index ,General Veterinary ,Proliferation index ,business.industry ,Significant difference ,Proliferation activity ,medicine.disease ,Gastrointestinal lymphoma ,World health ,Pathology and Forensic Medicine ,Lymphoma ,Dogs ,Ki-67 Antigen ,Immunophenotyping ,Mitotic Index ,medicine ,Animals ,Dog Diseases ,Lymphoma, Large B-Cell, Diffuse ,business ,Cell Proliferation ,Gastrointestinal Neoplasms - Abstract
Summary Gastrointestinal lymphomas are uncommon in dogs and little is known about their distinct subtypes or proliferation rate. The aim of this study was to stratify 33 canine gastrointestinal lymphoma samples according to the latest World Health Organization classification and to determine the Ki67 proliferation index by manual counting, digital image analysis and visual estimation. The Ki67 index was then correlated with subtype, immunophenotype, mitotic index, grade and tumour location. The mitotic index correlated positively with the Ki67 index. A significantly higher number of Ki67-positive cells was found in enteropathy-associated T-cell lymphoma type I and in diffuse large B-cell lymphoma compared with enteropathy-associated T-cell lymphoma type II. There was also a significant difference in Ki67 immunolabelled cells between grade 1 and grade 2 lymphomas. Moderate agreement was found between the Ki67 index as obtained by manual counting and visual estimation, but there was strong agreement between manual counting and digital image analysis. The user-friendly digital imaging system used in this study could have potential for future determination of the Ki67 index in lymphoid neoplasms.
- Published
- 2021
11. Cost‐effectiveness and budget impact of whole blood pathogen reduction in Ghana
- Author
-
Betty Norman, Brian Custer, Shirley Owusu-Ofori, W. Alton Russell, Alex Owusu-Ofori, and Eileen Micah
- Subjects
business.industry ,Cost effectiveness ,Transmission (medicine) ,Blood Safety ,Cost-Benefit Analysis ,Incidence (epidemiology) ,Immunology ,Transfusion Reaction ,Hematology ,medicine.disease ,Communicable Diseases ,Ghana ,Sepsis ,Environmental health ,Health care ,medicine ,Humans ,Immunology and Allergy ,business ,Adverse effect ,Malaria ,Whole blood - Abstract
Background Despite the promise of pathogen reduction for reducing transfusion-associated adverse events in sub-Saharan Africa, no health-economic assessment is publicly available. Study design and methods We developed a mathematical risk reduction model to estimate the impact of nationwide whole blood pathogen reduction in Ghana on the incidence of six infectious and one non-infectious transfusion-associated adverse events. We estimated the lifetime direct healthcare costs and disability-adjusted life years lost for each adverse event. For HIV, HCV, and HBV, we simulated disease progression using Markov models, accounting for the likelihood and timing of clinical detection and treatment. We performed probabilistic and univariate sensitivity analysis. Results Adding whole blood pathogen reduction to Ghana's blood safety portfolio would avert an estimated 19,898 (11,948-27,353) adverse events and 38,491 (16,444-67,118) disability-adjusted life years annually, primarily by averting sepsis (49%) and malaria (31%) infections. One year of pathogen reduction would cost an estimated $8,037,191 ($6,381,946-$9,880,760) and eliminate $8,656,389 ($4,462,614-$13,469,448) in direct healthcare spending on transfusion-associated adverse events. We estimate a 58% probability that the addition of pathogen reduction would reduce overall direct healthcare spending. Findings were most sensitive to uncertainty in the probability that a bacterially contaminated blood donation causes sepsis. Conclusion Whole blood pathogen reduction would substantially reduce the burden of known transfusion-associated adverse events in Ghana and may reduce overall healthcare spending. Additional benefits not captured by this analysis may include averting secondary transmission of infectious diseases, reducing non-medical costs, and averting new or re-emerging transfusion-transmitted infections.
- Published
- 2021
12. C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates
- Author
-
Zachary W. Fitch, John D. Lambris, Miriam Manook, Edimara S. Reis, Paul M. Schroder, Robin Schmitz, Mingqing Song, Sanjay Khandelwal, Stuart J. Knechtle, Janghoon Yoon, John S. Yi, Ashley Y. Choi, Alton B. Farris, Gowthami M. Arepally, and Jean Kwun
- Subjects
Graft Rejection ,Male ,Globulin ,Pyridones ,T-Lymphocytes ,Science ,General Physics and Astronomy ,Renal function ,Lymphocyte Activation ,General Biochemistry, Genetics and Molecular Biology ,B-cell proliferation ,Antibodies ,Medicine ,Animals ,Transplantation, Homologous ,Cell Proliferation ,B-Lymphocytes ,Multidisciplinary ,biology ,business.industry ,Graft Survival ,General Chemistry ,Complement C3 ,Kidney Transplantation ,Macaca mulatta ,Antibody mediated rejection ,Immunology ,biology.protein ,Renal allograft ,Lymphocyte activation ,Cytokines ,C3 complement ,Antibody ,business - Abstract
Sensitized kidney transplant recipients experience high rates of antibody-mediated rejection due to the presence of donor-specific antibodies and immunologic memory. Here we show that transient peri-transplant treatment with the central complement component C3 inhibitor Cp40 significantly prolongs median allograft survival in a sensitized nonhuman primate model. Despite donor-specific antibody levels remaining high, fifty percent of Cp40-treated primates maintain normal kidney function beyond the last day of treatment. Interestingly, presence of antibodies of the IgM class associates with reduced median graft survival (8 vs. 40 days; p = 0.02). Cp40 does not alter lymphocyte depletion by rhesus-specific anti-thymocyte globulin, but inhibits lymphocyte activation and proliferation, resulting in reduced antibody-mediated injury and complement deposition. In summary, Cp40 prevents acute antibody-mediated rejection and prolongs graft survival in primates, and inhibits T and B cell activation and proliferation, suggesting an immunomodulatory effect beyond its direct impact on antibody-mediated injury. Donor-specific antibodies in sensitized recipients may cause kidney transplant rejection. Here the authors show that complement component C3 inhibition prolongs graft survival by inhibiting T and B cell proliferation/activation and hence tissue injury, despite antibody levels remaining unaffected.
- Published
- 2021
13. Collagen Type III and VI Remodeling Biomarkers Are Associated with Kidney Fibrosis in Lupus Nephritis
- Author
-
Wendy I. White, Ahmad Akhgar, S. Sam Lim, Jason Cobb, Monica Battle, Federica Genovese, Morten A. Karsdal, Alton B. Farris, and Dominic Sinibaldi
- Subjects
Pathology ,medicine.medical_specialty ,Kidney ,medicine.diagnostic_test ,business.industry ,Tubular atrophy ,Lupus nephritis ,Renal function ,General Medicine ,Urine ,medicine.disease ,Fibrosis ,Lupus Nephritis ,Extracellular matrix ,Collagen Type III ,medicine.anatomical_structure ,Biopsy ,Humans ,Medicine ,business ,Biomarkers ,Original Investigation - Abstract
BACKGROUND: Lupus nephritis (LN) occurs in
- Published
- 2021
14. 'You were lying in limbo and you knew nothing': a thematic analysis of the information needs of spinal cord injured patients and family members in acute care
- Author
-
Éimear Smith, Maeve Nolan, Clodagh Cogley, and Paul D’Alton
- Subjects
medicine.medical_specialty ,business.industry ,Rehabilitation ,Information needs ,Spinal cord ,medicine.disease ,Physical medicine and rehabilitation ,medicine.anatomical_structure ,Order (business) ,Nothing ,Acute care ,medicine ,Thematic analysis ,business ,Spinal cord injury ,Lying - Abstract
To address the lack of research on the information needs of spinal cord injured (SCI) patients and family members in acute care, in order to inform the provision of appropriate information supports...
- Published
- 2021
15. Barriers to cancer care for people with significant mental health difficulties: What healthcare staff say?
- Author
-
Ann Nuzum, Paul D’Alton, Varsha Eswara Murthy, Clodagh Cogley, Derval McCormack, Seán Langford, Zoe McDonnell, Fiona Craddock, and Rachel O'Meara
- Subjects
education.field_of_study ,business.industry ,Health Personnel ,Population ,Psycho-oncology ,Social Workers ,Experimental and Cognitive Psychology ,Context (language use) ,Mental illness ,medicine.disease ,Care provision ,Mental health ,Psychiatry and Mental health ,Mental Health ,Oncology ,Nursing ,Neoplasms ,Health care ,Humans ,Medicine ,Thematic analysis ,business ,education ,Delivery of Health Care ,Qualitative Research - Abstract
Objectives Despite similar rates in cancer morbidity, patients with comorbid significant mental health difficulties (SMHD) experience higher mortality rates. This population has largely been neglected in cancer care research. Little is known about how to improve cancer outcomes for patients with SMHD. The aim of this research is to explore the views of healthcare professionals concerning the provision of cancer care to individuals with SMHD in an Irish context. Methods Semi-structured interviews were conducted with healthcare professionals (n = 28) providing care to people with SMHD and cancer. This included oncology and psychiatry consultants (n = 10); clinical nurse specialists (n = 8); clinical psychologists (n = 6); and medical social workers (n = 4). Data were analysed using thematic analysis. Results Four overarching themes were generated from the data highlighting the challenges associated with healthcare provision for this cohort. The themes were: Fragmentation of Care, Healthcare Providers' Understanding of SMHD, Complex Nature of Presentation, and Specialised Care Needs. Conclusions The findings contribute to advancing our understanding of cancer care provision for patients with SMHD. They identify important barriers and facilitators to cancer care provision for this population from the perspective of healthcare professionals in Ireland. These findings will help to shape future research and contribute to improving the quality-of-care for people with SMHD and cancer.
- Published
- 2021
16. The eARTISTS Media and Information Literacy Model for Managing Access to Quality Information
- Author
-
Jagtar Singh and Alton Grizzle
- Subjects
Knowledge management ,Computer science ,business.industry ,Information literacy ,Library and Information Sciences ,business ,Quality information - Abstract
Information is necessary for eliminating uncertainty and facilitating decision-making. Quality of decisions depends upon the quality of information available to the stakeholders. But to manage access to quality information, information seekers have to depend upon different sources of information, media, and other information providers. Unfortunately, the commercial media is controlled by corporate tycoons, governments, politicians and various non-government organisations (NGOs). These information providers have some motive behind the stories flashed by them. Hence, media and information literacy (MIL) skills are necessary for ascertaining truth behind the story. Earlier, information literacy and media literacy were used as separate concepts but now UNESCO is using (MIL) as a composite concept, appreciating the symbiosis between media and information. This article gives an overview of a few MIL related developments and describes the e-ARTISTS MIL Model developed by Jagtar Singh and Alton Grizzle. Differentiating the e-ARTISTS Model from the Big6 Model and the Empowering 8 Model of Information Literacy, it justifies the need for e-ARTISTS MIL Model for managing timely access to quality information for facilitating quality decision-making.
- Published
- 2021
17. Influenza Complicating Delivery Hospitalization and Its Association With Severe Maternal Morbidity in the United States, 2000–2018
- Author
-
Brittany Arditi, Timothy Wen, Laura E. Riley, Mary E. D'Alton, Alexander M. Friedman, Kartik K. Venkatesh, Nasim C. Sobhani, and Mary E. Norton
- Subjects
ARDS ,Pregnancy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Obstetrics and Gynecology ,Maternal morbidity ,medicine.disease ,Sepsis ,Increased risk ,Relative risk ,Emergency medicine ,medicine ,Intubation ,Maternal death ,business - Abstract
OBJECTIVE To characterize trends of an influenza diagnosis at delivery hospitalization and its association with severe maternal morbidity. METHODS We conducted a repeated cross-sectional analysis of delivery hospitalizations using the Nationwide Inpatient Sample from 2000 to 2018. We assessed the association between an influenza diagnosis at delivery hospitalization and severe maternal morbidity excluding transfusion per Centers for Disease Control and Prevention criteria. Secondary outcomes included maternal death and morbidity measures associated with influenza (mechanical intubation and ventilation, sepsis and shock, and acute respiratory distress syndrome [ARDS]) and obstetric complications (preterm birth and hypertensive disorders of pregnancy). We assessed trends of severe maternal morbidity by annual influenza season and the association between influenza and severe maternal morbidity using multivariable log-linear regression, adjusting for demographic, clinical, and hospital characteristics. RESULTS Of 74.7 million delivery hospitalizations, 23 per 10,000 were complicated by an influenza diagnosis. The rate of severe maternal morbidity was higher with an influenza diagnosis compared with those without influenza (86-410 cases vs 53-70 cases/10,000 delivery hospitalizations). Women with an influenza diagnosis at delivery hospitalization were at an increased risk of severe maternal morbidity compared with those without influenza (2.3 vs 0.7%; adjusted risk ratio 2.24, 95% CI 2.17-2.31). This association held for maternal death, mechanical intubation, sepsis and shock, and ARDS-as well as obstetric complications, including preterm birth and hypertensive disorders of pregnancy. CONCLUSION Pregnant women with influenza are at increased risk of severe maternal morbidity, as well as influenza-related maternal and obstetric complications. These results emphasize the importance of primary prevention and recognition of influenza infection during pregnancy to reduce downstream maternal morbidity and mortality.
- Published
- 2021
18. PRO‐C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD
- Author
-
Miriam B. Vos, Diane E. Shevell, Diana Julie Leeming, Rebecca Cleeton, Catherine C. Cohen, Morten A. Karsdal, Shelley A. Caltharp, Alton B. Farris, Elizabeth M. Sinclair, Mette Juul Nielsen, and Eduardo Castillo‐Leon
- Subjects
Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,Adolescent ,Osteocalcin ,RC799-869 ,Chronic liver disease ,Severity of Illness Index ,Gastroenterology ,Collagen Type I ,Bone remodeling ,N-terminal telopeptide ,Non-alcoholic Fatty Liver Disease ,Fibrosis ,Interquartile range ,Internal medicine ,Nonalcoholic fatty liver disease ,medicine ,Humans ,Child ,Hepatology ,medicine.diagnostic_test ,business.industry ,Puberty ,Age Factors ,Original Articles ,Complement C3 ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,Cross-Sectional Studies ,Liver biopsy ,Original Article ,Female ,Bone Remodeling ,Peptides ,business ,Biomarkers - Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease in children and may lead to cirrhosis requiring liver transplant. Thus, prompt diagnosis of advanced fibrosis is essential. Our objectives were to examine PRO‐C3 (a neo‐epitope pro‐peptide of type III collagen formation) levels across childhood/adolescence and associations with advanced fibrosis in pediatric NAFLD. This cross‐sectional study included 88 children and adolescents with biopsy‐proven NAFLD (mean age: 13.9 ± 2.9 years, 71% male) and 65 healthy participants (11.8 ± 4.5 years, 38% male). PRO‐C3, and the bone remodeling biomarkers C‐terminal telopeptide of type I collagen (CTX‐I; bone resorption) and osteocalcin (N‐MID; bone formation), were measured in serum by enzyme‐linked immunosorbent assay. Fibrosis was assessed by liver biopsy in participants with NAFLD, who were categorized as having advanced (Ishak score ≥ 3) or none/mild fibrosis (Ishak score ≤ 2). Overall, PRO‐C3 was similar in participants with NAFLD (median [interquartile range]: 20.6 [15.8, 25.9] ng/mL) versus healthy participants (19.0 [13.8, 26.0] ng/mL), but was significantly lower in older adolescents ≥ 15 years old (16.4 [13.0, 21.2] ng/mL) compared with children ≤ 10 years old (22.9 [18.1, 28.4] ng/mL; P
- Published
- 2021
19. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- Author
-
Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Y-S Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke, Rafael Morales Barrera, Aude Fléchon, Seyda Gunduz, Yohann Loriot, Alejo Rodriguez-Vida, Ronac Mamtani, Evan Y Yu, Kijoeng Nam, Kentaro Imai, Blanca Homet Moreno, Ajjai Alva, Diana Vera Cascallar, Mirta Varela, Mauricio Fernandez Lazzaro, Diego Lucas Kaen, Gabriela Gatica, David Hugo Flores, Agustin Falco, Matias Molina, Filip Van Aelst, Brieuc Sautois, Jean-Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sergio J Azevedo, Gisele Marinho, Joao Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, Andre Poisl Fay, Joel Gingerich, Cristiano Ferrario, Kylea Potvin, Marie Vanhuyse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, Jose Luis Leal, Francisco Francisco, Carolina Ibanez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Flechon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross-Goupil, Stephane Culine, Gwenaelle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David Pfister, Carsten Ohlman, Michael Stoeckle, Manfred Wirth, Anja Lorch, Guenter Niegisch, Peter J Goebell, Martin Boegemann, Axel Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian Thomas, Thomas Hoefner, Andras Telekes, Judit Erzsebet Kosa, Janos Revesz, Gyorgy Bodoky, Tibor Csoszi, Andras Csejtei, Lajos Geczi, Agnes Ruzsa, Zsuzsanna Kolonics, Jozsef Erfan, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Kejzman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger, Keren Rouvinov, David Sarid, Satoshi Fukasawa, Gaku Arai, Akito Yamaguchi, Akira Yokomizo, Tatsuya Takayama, Hidefumi Kinoshita, Eiji Kikuchi, Ryuichi Mizuno, Yasuhisa Fujii, Naoto Sassa, Yoshihisa Matsukawa, Kiyohide Fujimoto, Toshiki Tanikawa, Yoshihiko Tomita, Kazuo Nishimura, Masao Tsujihata, Masafumi Oyama, Naoya Masumori, Hiroomi Kanayama, Toshimi Takano, Yuji Miura, Jun Miyazaki, Akira Joraku, Tomokazu Kimura, Yoshiaki Yamamoto, Kazuki Kobayashi, Ronald De Wit, Maureen Aarts, Winald Gerritsen, Maartje Los, Laurens Beerepoot, Adel Izmailov, Sergey Igorevich Gorelov, Boris Yakovlevich Alekseev, Andrey Semenov, Vladimir Anatolyevich Kostorov, Sergey M Alekseev, Alexander Zyryanov, Vasiliy Nikolaevich Oschepkov, Vladimir Aleksandrovich Shidin, Vladimir Ivanovich Vladimirov, Rustem Airatovich Gafanov, Petr Alexandrovich Karlov, David Brian Anderson, Lucinda Shepherd, Graham Lawrence Cohen, Bernardo Louis Rapoport, Paul Ruff, Nari Lee, Woo Kyun Bae, Hyo Jin Lee, Urbano Anido Herranz, Enrique Grande, Teresa Alonso Gordoa, Josep Guma Padro, Daniel Castellano Gauna, Jose Angel Arranz, Jose Munoz Langa, Regina Girones Sarrio, Alvaro Montesa Pino, Maria Jose Juan Fita, Yu-Li Su, Yung-Chang Lin, Wen-Pin Su, Ying-Chun Shen, Yen-Hwa Chang, Yi-Hsiu Huang, Virote Sriuranpong, Phichai Chansriwong, Vichien Srimuninnimit, Pongwut Danchaivijitr, Huseyin Abali, Sinan Yavuz, Ozgur Ozyilkan, Mehmet Ali Nahit Sendur, Meltem Ekenel, Mustafa Ozguroglu, Cagatay Arslan, Mustafa Ozdogan, Alison Birtle, Robert Huddart, Maria de Santis, Anjali Zarkar, Linda Evans, Syed Hussain, Christopher DiSimone, Antonio F Muina, Peter Schlegel, Haresh S Jhangiani, Michael Harrison, Dennis E Slater, David Wright, Ivor J Percent, Jianqing Lin, Clara Hwang, Sumati Gupta, Madhuri Bajaj, Robert Galamaga, John Eklund, James Wallace, Mikhail Shtivelband, Jason Jung-Gon Suh, Nafisa Burhani, Matthew Eadens, Krishna Gunturu, Earle Burgess, John Wong, Arvind Chaudhry, Peter Van Veldhuizen, Stephanie Graff, Christian A Thomas, Ian D Schnadig, Benedito Carneiro, Maha Hussain, Alicia Morgans, John T Fitzharris, Ira A Oliff, Jacqueline Vuky, Ralph Hauke, Ari Baron, Monika Joshi, Britt H Bolemon, Peter Jiang, Anthony E Mega, Maurice Markus, Nicklas Pfanzelter, William Eyre Lawler, Patrick Wayne Cobb, Jay G Courtright, Sharad Jain, Gurjyot Doshi, Vijay K Gunuganti, Oliver Alton Sartor, Scott W Cole, Hani Babiker, Edward M Uchio, Alexandra Drakaki, Heather D Mannuel, Elizabeth Guancial, Chunkit Fung, Anthony Charles, Robert J Amato, Yull Arriaga, Isaac Bowman, Steven Ades, Robert Dreicer, Evan Yu, David I Quinn, Mark Fleming, University of Zurich, Powles, Thomas, KEYNOTE-361 Investigators, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, and UCL - (SLuc) Unité d'oncologie médicale
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Population ,610 Medicine & health ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,Deoxycytidine ,Gastroenterology ,Carboplatin ,03 medical and health sciences ,chemistry.chemical_compound ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Clinical endpoint ,medicine ,Humans ,030212 general & internal medicine ,Progression-free survival ,education ,Immune Checkpoint Inhibitors ,Aged ,Chemotherapy ,education.field_of_study ,business.industry ,Carcinoma ,Hazard ratio ,Middle Aged ,Gemcitabine ,Progression-Free Survival ,Urinary Bladder Neoplasms ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,10032 Clinic for Oncology and Hematology ,Disease Progression ,Female ,2730 Oncology ,Human medicine ,Cisplatin ,Urothelium ,business ,medicine.drug - Abstract
Summary Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma. Methods KEYNOTE-361 is a randomised, open-label, phase 3 trial of patients aged at least 18 years, with untreated, locally advanced, unresectable, or metastatic urothelial carcinoma, with an Eastern Cooperative Oncology Group performance status of up to 2. Eligible patients were enrolled from 201 medical centres in 21 countries and randomly allocated (1:1:1) via an interactive voice-web response system to intravenous pembrolizumab 200 mg every 3 weeks for a maximum of 35 cycles plus intravenous chemotherapy (gemcitabine [1000 mg/m2] on days 1 and 8 and investigator's choice of cisplatin [70 mg/m2] or carboplatin [area under the curve 5] on day 1 of every 3-week cycle) for a maximum of six cycles, pembrolizumab alone, or chemotherapy alone, stratified by choice of platinum therapy and PD-L1 combined positive score (CPS). Neither patients nor investigators were masked to the treatment assignment or CPS. At protocol-specified final analysis, sequential hypothesis testing began with superiority of pembrolizumab plus chemotherapy versus chemotherapy alone in the total population (all patients randomly allocated to a treatment) for the dual primary endpoints of progression-free survival (p value boundary 0·0019), assessed by masked, independent central review, and overall survival (p value boundary 0·0142), followed by non-inferiority and superiority of overall survival for pembrolizumab versus chemotherapy in the patient population with CPS of at least 10 and in the total population (also a primary endpoint). Safety was assessed in the as-treated population (all patients who received at least one dose of study treatment). This study is completed and is no longer enrolling patients, and is registered at ClinicalTrials.gov , number NCT02853305 . Findings Between Oct 19, 2016 and June 29, 2018, 1010 patients were enrolled and allocated to receive pembrolizumab plus chemotherapy (n=351), pembrolizumab monotherapy (n=307), or chemotherapy alone (n=352). Median follow-up was 31·7 months (IQR 27·7–36·0). Pembrolizumab plus chemotherapy versus chemotherapy did not significantly improve progression-free survival, with a median progression-free survival of 8·3 months (95% CI 7·5–8·5) in the pembrolizumab plus chemotherapy group versus 7·1 months (6·4–7·9) in the chemotherapy group (hazard ratio [HR] 0·78, 95% CI 0·65–0·93; p=0·0033), or overall survival, with a median overall survival of 17·0 months (14·5–19·5) in the pembrolizumab plus chemotherapy group versus 14·3 months (12·3–16·7) in the chemotherapy group (0·86, 0·72–1·02; p=0·0407). No further formal statistical hypothesis testing was done. In analyses of overall survival with pembrolizumab versus chemotherapy (now exploratory based on hierarchical statistical testing), overall survival was similar between these treatment groups, both in the total population (15·6 months [95% CI 12·1–17·9] with pembrolizumab vs 14·3 months [12·3–16·7] with chemotherapy; HR 0·92, 95% CI 0·77–1·11) and the population with CPS of at least 10 (16·1 months [13·6–19·9] with pembrolizumab vs 15·2 months [11·6–23·3] with chemotherapy; 1·01, 0·77–1·32). The most common grade 3 or 4 adverse event attributed to study treatment was anaemia with pembrolizumab plus chemotherapy (104 [30%] of 349 patients) or chemotherapy alone (112 [33%] of 342 patients), and diarrhoea, fatigue, and hyponatraemia (each affecting four [1%] of 302 patients) with pembrolizumab alone. Six (1%) of 1010 patients died due to an adverse event attributed to study treatment; two patients in each treatment group. One each occurred due to cardiac arrest and device-related sepsis in the pembrolizumab plus chemotherapy group, one each due to cardiac failure and malignant neoplasm progression in the pembrolizumab group, and one each due to myocardial infarction and ischaemic colitis in the chemotherapy group. Interpretation The addition of pembrolizumab to first-line platinum-based chemotherapy did not significantly improve efficacy and should not be widely adopted for treatment of advanced urothelial carcinoma. Funding Merck Sharp and Dohme, a subsidiary of Merck, Kenilworth, NJ, USA.
- Published
- 2021
20. Relationships and Spatial Structure of Soil Physical Properties in a Ten-Year Corn-Cotton Rotation Field
- Author
-
Peter A. Y. Ampim, Samuel G.K. Adiku, and Alton B. Johnson
- Subjects
business.product_category ,Soil test ,Soil texture ,Geography, Planning and Development ,Soil science ,Bulk density ,Texture (geology) ,Plough ,Pedotransfer function ,Loam ,Earth and Planetary Sciences (miscellaneous) ,Spatial variability ,business ,Mathematics - Abstract
This study quantified the relationships between soil, textural, and hydraulic properties at the field-scale for a conventional tilled Memphis silt loam that had undergone a 10-year corn and cotton rotation and described their spatial variability. Composite soil samples collected from the plow layer at 272 nodes on 15 x 15 m grids were analyzed for texture and bulk density. These values were used as pedotransfer functions to predict unsaturated (Ko) and saturated hydraulic (Ks) conductivities as well as the van Genuchten curve shape parameters α and n. Regression analyses quantified relationships between the measured and model predicted soil properties. While correlations between textural and model predicted soil properties including bulk density were significant (p
- Published
- 2021
21. 177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience
- Author
-
Samer Ezziddin, Giovanni Paganelli, Jörg Elllinger, Gero Kramer, Alton O. Sartor, Avivit Peer, Martin Bögemann, John Sylvester, Jeffrey Meltzer, Per Sandström, Frank Verholen, Danny Y. Song, Luke T. Nordquist, Markus Essler, and Christian la Fougère
- Subjects
Oncology ,Radium-223 ,education.field_of_study ,medicine.medical_specialty ,business.industry ,Population ,Small sample ,Castration resistant ,urologic and male genital diseases ,medicine.disease ,Prostate cancer ,Docetaxel ,Internal medicine ,Radionuclide therapy ,Glutamate carboxypeptidase II ,Medicine ,Radiology, Nuclear Medicine and imaging ,business ,education ,medicine.drug - Abstract
We analyzed real-world clinical outcomes of sequential alpha-/beta-emitter therapy for metastatic castration-resistant prostate cancer (mCRPC). Methods: We assessed safety and overall survival in 26 patients who received lutetium-177-prostate-specific membrane antigen ligand (177Lu-PSMA) following radium-223 in the ongoing non-interventional Radium-223 alpha Emitter Agent Safety Study in mCRPC popUlation for long-teRm Evaluation (REASSURE; NCT02141438). Results: Patients received radium-223 for a median 6 injections and subsequent 177Lu-PSMA for a median 3.5 months (≥4th therapy in 69%). The median time between radium-223 and 177Lu-PSMA treatment was 8 months (range 1-31). Grade 3 hematologic events occurred in 9/26 patients (during or after 177Lu-PSMA treatment in 5/9 patients; 8/9 patients had also received docetaxel). Median overall survival was 28.0 months from radium-223 start and 13.2 months from 177Lu-PSMA start. Conclusion: Although the small sample size precludes definitive conclusions, these preliminary data, especially 177Lu-PSMA treatment duration, suggest feasibility of 177Lu-PSMA use after radium-223 in this real-world setting.
- Published
- 2021
22. Maternal morbidity and mortality associated with epilepsy
- Author
-
Alison M. Pack, Brian T. Bateman, Jason D. Wright, Alexander M. Friedman, Rachael J Benson, Cynthia Gyamfi-Bannerman, Yongmei Huang, and Mary E. D'Alton
- Subjects
Pediatrics ,medicine.medical_specialty ,Placenta ,Maternal morbidity ,Cohort Studies ,03 medical and health sciences ,Epilepsy ,0302 clinical medicine ,Pregnancy ,Humans ,Medicine ,030212 general & internal medicine ,Abruptio Placentae ,business.industry ,Infant, Newborn ,Pregnancy Outcome ,Obstetrics and Gynecology ,medicine.disease ,Maternal Mortality ,Increased risk ,Pediatrics, Perinatology and Child Health ,Premature Birth ,Female ,Anticonvulsants ,business ,030217 neurology & neurosurgery - Abstract
Prior research demonstrated large increased risk for maternal mortality among women with epilepsy. The objective of this study was to estimate risk for adverse maternal outcomes during delivery hospitalizations among women with epilepsy. Truven Health MarketScan databases were used to compare risk for adverse maternal outcomes during delivery hospitalizations based upon whether there was diagnosis of epilepsy and receipt of anti-epileptic drugs prior to delivery. Outcomes included: (i) death during delivery hospitalization, (ii) severe maternal morbidity, (iii) cesarean delivery, (iv) postpartum hemorrhage, (v) placental abruption, (vi) preeclampsia, (vii) preterm delivery, (viii) premature rupture of membranes, and (ix) stillbirth. Adjusted models including hospital and demographic factors were performed with adjusted risk ratios (aRR) with 95% CIs as measures of effect. Women with epilepsy prior to delivery who received antiepileptic drugs (n = 6019) during pregnancy were not at increased risk for mortality with no deaths occurring in this group (p = .27). Risk for severe maternal morbidity in this group was approximately double (aRR 2.16, 95% CI 1.86–2.51) with risks for other outcomes including placental abruption (aRR 1.29, 95% CI 1.04–1.60), cesarean delivery (aRR 1.14, 95% CI 1.10–1.18), and preterm delivery (aRR 1.25, 95% CI 1.15–1.35) slightly increased compared to women without seizures. No significant difference in mortality risk was found for women with epilepsy. Increased risk for other adverse maternal outcomes for women with epilepsy on antiepileptics was modest.
- Published
- 2021
23. A Systematic Review and Meta-Analysis of the Association Between Perceived Injustice and Depression
- Author
-
Paul D’Alton, Susan Fox, Julie Lynch, and Keith Gaynor
- Subjects
media_common.quotation_subject ,PsycINFO ,CINAHL ,Anger ,03 medical and health sciences ,0302 clinical medicine ,Social Justice ,030202 anesthesiology ,medicine ,Humans ,Risk factor ,Depression (differential diagnoses) ,media_common ,Depression ,business.industry ,Chronic pain ,medicine.disease ,Mental health ,Anesthesiology and Pain Medicine ,Social Perception ,Neurology ,Meta-analysis ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Clinical psychology - Abstract
Perceived injustice is increasingly recognized as a risk factor for problematic recovery, with a growing body of evidence documenting its association with heightened pain, disability, medication use, anger and post-traumatic stress. The aim of this paper was to systematically review and critically appraise the association between perceived injustice and depressive symptomatology across a wide range of medical and mental health populations, including acute and chronic pain samples. A search of published, English language studies in the PubMed, EMBASE, CINAHL, and PsycINFO databases from 1990 to June 2020 was performed. Thirty-three studies met inclusion criteria with a total sample of 5,425 individuals (61% female), primarily with acute injury or chronic pain. Results indicated a moderate to strong positive association between perceived injustice and depressive symptomatology (meta-analysis pooled effect of r = .57, 95% confidence interval [.55, .58], P.001). A narrative synthesis of regression models indicated standardized beta coefficients between .19 and .66, with perceived injustice consistently contributing significant unique variance to the prediction of depression in final regression equations. Selection bias and response bias were common limitations in the studies. The clinical implications of an association between injustice and depression in acute and chronic pain are discussed. PROSPERO: CRD42019143465. PERSPECTIVE: This review demonstrates that in acute injury and chronic pain samples, perceived injustice is associated with depression. These findings could help clinicians in the field of pain and rehabilitation identify who may be at greater risk for a problematic recovery trajectory.
- Published
- 2021
24. Collagen Type III Glomerulopathy
- Author
-
Lois J. Arend, Anna Lisa V. Wilson, Rohan Rengen, Alton B. Farris, and Francesca Costigliolo
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,MEDLINE ,medicine.disease ,Diseases of the genitourinary system. Urology ,Collagen Type III ,Text mining ,Nephrology ,Glomerulopathy ,Medicine ,RC870-923 ,Nephrology Rounds ,business - Published
- 2021
25. HPV vaccine communication training in healthcare systems: Evaluating a train-the-trainer model
- Author
-
Susan Alton Dailey, Noel T. Brewer, Liddy Hora, Timothy McCoy, Chloe G. Mitchell, Kim Tichy, and Marcie Fisher-Borne
- Subjects
Health Knowledge, Attitudes, Practice ,medicine.medical_specialty ,Adolescent ,education ,Psychological intervention ,Primary care ,Train the trainer ,03 medical and health sciences ,0302 clinical medicine ,Physicians ,030225 pediatrics ,Intervention (counseling) ,medicine ,Humans ,Papillomavirus Vaccines ,030212 general & internal medicine ,Child ,Motivation ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Communication ,Papillomavirus Infections ,Vaccination ,Public Health, Environmental and Occupational Health ,Hpv vaccination ,Infectious Diseases ,Family medicine ,Molecular Medicine ,Clinical staff ,business ,Delivery of Health Care ,Adolescent health ,Healthcare system - Abstract
BACKGROUND Large healthcare systems provide an opportunity to disseminate evidence-based interventions to primary care. We evaluated the impact of a train-the-trainer model in two large systems to disseminate the Announcement Approach Training, which teaches providers to communicate about HPV vaccination more effectively. METHODS In collaboration with the American Cancer Society, we partnered with two midwestern healthcare systems that served over 77,000 patients ages 11 through 17. Both systems hosted a 2-hour train-the-trainer workshop. Providers from one system then conducted in-person 1-hour CME-eligible trainings, using our standard slide set and script (available at hpvIQ.org). The other system did not implement trainings, providing a natural experiment. RESULTS The train-the-trainer workshop included physicians, nurses and other clinical staff (n = 11/13 for intervention/comparison systems). The intervention system delivered 18 trainings to 234 physicians, nurses, and other clinic staff. From baseline to 6-month follow-up, the intervention system had an increase in HPV vaccine uptake that was larger than that of the comparison system for adolescents ages 11 through 12 (1.9%, p = .002) and ages 13 through 17 (1.5%, p = .015). Attending the training was associated with increased intentions to routinely recommend HPV vaccine when patients turn 11 or 12 (mean 4.19 (SD = 0.95) vs. 4.43 (SD = 0.83) as well as increased positive vaccine attitudes, self-efficacy, and norms (all p
- Published
- 2021
26. Trends in and Factors Associated With Episiotomy in the Setting of Nonoperative Vaginal Delivery, 2000–2018
- Author
-
Yongmei Huang, Teresa C Logue, Jason D. Wright, Alexander M. Friedman, Timothy Wen, Brittany Arditi, and Mary E. D'Alton
- Subjects
Episiotomy ,medicine.medical_specialty ,Vaginal delivery ,Obstetrics ,business.industry ,medicine.medical_treatment ,medicine ,Obstetrics and Gynecology ,business - Published
- 2021
27. SiPM-matrix readout of two-phase argon detectors using electroluminescence in the visible and near infrared range
- Author
-
F. Pietropaolo, Min-Xin Guan, S. Rescia, Federica Villa, F. Coccetti, A. Sheshukov, D. A. Semenov, Alberto Masoni, C. Savarese, F. Ameli, S. Bussino, Jocelyn Monroe, Paola Sala, Lelio Luzzi, R. Tartaglia, B. Hosseini, Chung-Yao Yang, I. Kochanek, Andrea Messina, S. Davini, A. V. Derbin, Paul H. Humble, V. Strickland, A. Franceschi, A. L. Hallin, P. Skensved, O. Smirnov, A. De Falco, C. Ripoli, E. Paoloni, B. Lehnert, E. Segreto, Laura A. Pellegrini, André Rubbia, Manuel Colocci, Aldo Ghisi, Marzio Nessi, V. Cocco, R. Graciani Diaz, Pietro Antonioli, M. G. Boulay, L. La Delfa, P. Cavalcante, V. Barbaryan, A.E. Bondar, W. Bonivento, C. Cantini, M. Lai, J. Mason, G. Fiorillo, Sara Sulis, L. P. Rignanese, T. N. Thorpe, Mariano Cadoni, T. Pollmann, E. V. Unzhakov, Q. Liqiang, Giovanni Covone, S. De Cecco, E. Scapparone, Andrea Gabrieli, Marino Simeone, C. Dionisi, N. Rossi, R. Stainforth, Mauro Marinelli, C. Regenfus, Gillian Kopp, Mauro Mariani, I. N. Machulin, G. De Guido, M. Lissia, Federico Perotti, S. S. Poudel, A. B. McDonald, G. Dellacasa, Carlo Muscas, M. Fernandez Diaz, Darren Price, George E. Froudakis, A. Oleinik, N. Canci, H. O. Back, G. De Rosa, O. Gorchakov, R. B. Vogelaar, G. K. Giovanetti, Simonetta Palmas, Marco Pallavicini, A. D. Martinez Rojas, W. Mu, V. Oleynikov, Paolo Attilio Pegoraro, F. Di Eusanio, M. Grab, An. Ianni, Rudi Lussana, G. L. Usai, Luciano Pandola, M. D. Skorokhvatov, E. Borisova, Pascal Pralavorio, F. Pazzona, M. Gromov, A. Grobov, M. M. Wojcik, G. Dolganov, S. Manecki, A. K. Alton, E. Frolov, J. Wahl, Anselmo Margotti, Xiang Xiao, I. Nikulin, Aldo Romani, Annalisa Vacca, E. Conde Vilda, O. Dadoun, V. N. Muratova, S. Cebrián, B. Bottino, M. L. Gligan, R. Milincic, J. A. Wilson, G. Zuzel, Thomas Alexander, M. D'Incecco, L. Romero, S. Murphy, C. L. Kendziora, A. Devoto, L. Di Noto, E. V. Hungerford, A. Asunskis, S. Westerdale, P. Agnes, Yanchu Wang, E. Sandford, B. Schlitzer, Stefania Moioli, C. Giganti, M. Downing, R. Santorelli, Rosario Nania, Alberto Tosi, Mario Patricio Padilla Martínez, A.V. Shchagin, A. Buzulutskov, M. Caravati, F. Raffaelli, P. Giampa, Davide Portaluppi, Fabrice Hubaut, C. J. Jillings, K. Pelczar, Cristiano Galbiati, L. Pagani, J. A. Nowak, A. Sotnikov, Y. Suvorov, M. Da Rocha Rolo, A. Ilyasov, Eric W. Hoppe, S. Abdelhakim, M. K. Daniel, J. Rode, L. Mapelli, F. Retiere, Han Wang, M. Garbini, D. De Gruttola, M. Haranczyk, R. Kugathasan, R. Bunker, Raffaele Ardito, V. Bocci, G. Di Pietro, Z. Ye, N. Funicello, A. S. Kubankin, D. Franco, A. Pocar, N. Levashko, W. Cheng, A. Mandarano, A. Caminata, V. Pesudo, F. Gabriele, Francesca Dordei, Pierre-Andre Amaudruz, A. Vishneva, F. Cossio, G. Batignani, A. Steri, M. Orsini, D. Santone, M. Ave, P. Garcia Abia, B. Celano, T. Mroz, Stefano Cavuoti, Francesco Ragusa, R. K. Haaland, A. Gendotti, Mario Giorgi, Jay W. Grate, Marcelo Braga Bueno Guerra, M. La Commara, A. M. Szelc, D. Gascon Fora, A. Castellani, S. Chashin, G. U. Lodi, Silvia Arcelli, E. Pantic, A. Tonazzo, Marco Sant, R. J. Wheadon, Maria Giuseppina Bisogni, M. Rescigno, Anton Empl, D. Cavazza, A. Navrer Agasson, R. Cereseto, M. Razeti, R. Ajaj, Nicomede Pelliccia, Xiujiang Li, S. Wu, M. Guerzoni, S. J. M. Peeters, Pasquale Arpaia, V. Nosov, J. Anstey, Craig E. Aalseth, Andrey Sokolov, Paolo Musico, Matteo Morrocchi, M. Cariello, E. Sanchez Garcia, T. Viant, A. Candela, M. Kuss, K. Kondo, S. Siddhanta, F. Edalatfar, G. Korga, M. Tuveri, A. A. Machado, C. Ghiano, B. R. Hackett, Gilda Scioli, I. J. Arnquist, C. Pellegrino, Giuseppe Longo, A. L. Renshaw, Valerio Ippolito, A. Moggi, F. Carnesecchi, L. Consiglio, Angelo Rivetti, S. Viel, Pierfranco Demontis, Andrea Alici, B. Harrop, O. Samoylov, P. Di Stefano, G. Bonfini, Piero Salatino, Richard M. Williams, G. Sobrero, M. Cadeddu, K. J. Keeter, Marco Grassi, A. Barrado Olmedo, E. Picciau, Ivone F. M. Albuquerque, S. Sanfilippo, Fausto Ortica, J. M. Cela Ruiz, C. Cicalò, T. Napolitano, P. N. Singh, Paolo Castello, S. Stracka, K. Fomenko, M. Zuffa, D. M. Asner, M. Lebois, B. Radics, L. Cifarelli, S. De Pasquale, Allen Seifert, Marisa Gulino, D. Marras, R. A. Giampaolo, J. Maricic, Michele Mascia, M. De Deo, M. Arba, S. Horikawa, I. D'Antone, S. M. Mari, A. S. Chepurnov, C. Filip, Mauro Citterio, Denis Korablev, E. Vázquez-Jáuregui, T. Miletic, Paolo Crivelli, J. Walding, G. Testera, Giuseppe Baldovino Suffritti, Centre de Physique des Particules de Marseille (CPPM), Aix Marseille Université (AMU)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), AstroParticule et Cosmologie (APC (UMR_7164)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Institut Fédératif de Recherche en Sciences et Ingénierie de la Santé (IFRESIS-ENSMSE), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-IFR143, Aalseth, C. E., Abdelhakim, S., Agnes, P., Ajaj, R., Albuquerque, I. F. M., Alexander, T., Alici, A., Alton, A. K., Amaudruz, P., Ameli, F., Anstey, J., Antonioli, P., Arba, M., Arcelli, S., Ardito, R., Arnquist, I. J., Arpaia, P., Asner, D. M., Asunskis, A., Ave, M., Back, H. O., Barbaryan, V., Barrado Olmedo, A., Batignani, G., Bisogni, M. G., Bocci, V., Bondar, A., Bonfini, G., Bonivento, W., Borisova, E., Bottino, B., Boulay, M. G., Bunker, R., Bussino, S., Buzulutskov, A., Cadeddu, M., Cadoni, M., Caminata, A., Canci, N., Candela, A., Cantini, C., Caravati, M., Cariello, M., Carnesecchi, F., Castellani, A., Castello, P., Cavalcante, P., Cavazza, D., Cavuoti, S., Cebrian, S., Cela Ruiz, J. M., Celano, B., Cereseto, R., Chashin, S., Cheng, W., Chepurnov, A., Cicalò, C., Cifarelli, L., Citterio, M., Coccetti, F., Cocco, V., Colocci, M., Conde Vilda, E., Consiglio, L., Cossio, F., Covone, G., Crivelli, P., D’Antone, I., D’Incecco, M., Da Rocha Rolo, M. D., Dadoun, O., Daniel, M., Davini, S., De Cecco, S., De Deo, M., De Falco, A., De Gruttola, D., De Guido, G., De Rosa, G., Dellacasa, G., Demontis, P., De Pasquale, S., Derbin, A. V., Devoto, A., Eusanio, F. Di, Di Noto, L., Di Pietro, G., Di Stefano, P., Dionisi, C., Dolganov, G., Dordei, F., Downing, M., Edalatfar, F., Empl, A., Fernandez Diaz, M., Filip, C., Fiorillo, G., Fomenko, K., Franceschi, A., Franco, D., Frolov, E., Froudakis, G. E., Funicello, N., Gabriele, F., Gabrieli, A., Galbiati, C., Garbini, M., Garcia Abia, P., Gascón Fora, D., Gendotti, A., Ghiano, C., Ghisi, A., Giampa, P., Giampaolo, R. A., Giganti, C., Giorgi, M. A., Giovanetti, G. K., Gligan, M. L., Gorchakov, O., Grab, M., Graciani Diaz, R., Grassi, M., Grate, J. W., Grobov, A., Gromov, M., Guan, M., Guerra, M. B. B., Guerzoni, M., Gulino, M., Haaland, R. K., Hackett, B. R., Hallin, A., Haranczyk, M., Harrop, B., Hoppe, E. W., Horikawa, S., Hosseini, B., Hubaut, F., Humble, P., Hungerford, E. V., Ianni, An., Ilyasov, A., Ippolito, V., Jillings, C., Keeter, K., Kendziora, C. L., Kochanek, I., Kondo, K., Kopp, G., Korablev, D., Korga, G., Kubankin, A., Kugathasan, R., Kuss, M., La Commara, M., La Delfa, L., Lai, M., Lebois, M., Lehnert, B., Levashko, N., Li, X., Liqiang, Q., Lissia, M., Lodi, G. U., Longo, G., Lussana, R., Luzzi, L., Machado, A. A., Machulin, I. N., Mandarano, A., Manecki, S., Mapelli, L., Margotti, A., Mari, S. M., Mariani, M., Maricic, J., Marinelli, M., Marras, D., Martínez, M., Martinez Rojas, A. D., Mascia, M., Mason, J., Masoni, A., Mcdonald, A. B., Messina, A., Miletic, T., Milincic, R., Moggi, A., Moioli, S., Monroe, J., Morrocchi, M., Mroz, T., Mu, W., Muratova, V. N., Murphy, S., Muscas, C., Musico, P., Nania, R., Napolitano, T., Navrer Agasson, A., Nessi, M., Nikulin, I., Nosov, V., Nowak, J. A., Oleinik, A., Oleynikov, V., Orsini, M., Ortica, F., Pagani, L., Pallavicini, M., Palmas, S., Pandola, L., Pantic, E., Paoloni, E., Pazzona, F., Peeters, S., Pegoraro, P. A., Pelczar, K., Pellegrini, L. A., Pellegrino, C., Pelliccia, N., Perotti, F., Pesudo, V., Picciau, E., Pietropaolo, F., Pocar, A., Pollmann, T. R., Portaluppi, D., Poudel, S. S., Pralavorio, P., Price, D., Radics, B., Raffaelli, F., Ragusa, F., Razeti, M., Regenfus, C., Renshaw, A. L., Rescia, S., Rescigno, M., Retiere, F., Rignanese, L. P., Ripoli, C., Rivetti, A., Rode, J., Romani, A., Romero, L., Rossi, N., Rubbia, A., Sala, P., Salatino, P., Samoylov, O., Sánchez García, E., Sandford, E., Sanfilippo, S., Sant, M., Santone, D., Santorelli, R., Savarese, C., Scapparone, E., Schlitzer, B., Scioli, G., Segreto, E., Seifert, A., Semenov, D. A., Shchagin, A., Sheshukov, A., Siddhanta, S., Simeone, M., Singh, P. N., Skensved, P., Skorokhvatov, M. D., Smirnov, O., Sobrero, G., Sokolov, A., Sotnikov, A., Stainforth, R., Steri, A., Stracka, S., Strickland, V., Suffritti, G. B., Sulis, S., Suvorov, Y., Szelc, A. M., Tartaglia, R., Testera, G., Thorpe, T., Tonazzo, A., Tosi, A., Tuveri, M., Unzhakov, E. V., Usai, G., Vacca, A., Vázquez-Jáuregui, E., Viant, T., Viel, S., Villa, F., Vishneva, A., Vogelaar, R. B., Wahl, J., Walding, J. J., Wang, H., Wang, Y., Westerdale, S., Wheadon, R. J., Williams, R., Wilson, J., Wojcik, Ma. M., Wojcik, Ma., Wu, S., Xiao, X., Yang, C., Ye, Z., Zuffa, M., Zuzel, G., Institut de Physique Nucléaire d'Orsay (IPNO), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physique Nucléaire et de Hautes Énergies (LPNHE (UMR_7585)), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Aalseth C.E., Abdelhakim S., Agnes P., Ajaj R., Albuquerque I.F.M., Alexander T., Alici A., Alton A.K., Amaudruz P., Ameli F., Anstey J., Antonioli P., Arba M., Arcelli S., Ardito R., Arnquist I.J., Arpaia P., Asner D.M., Asunskis A., Ave M., Back H.O., Barbaryan V., Barrado Olmedo A., Batignani G., Bisogni M.G., Bocci V., Bondar A., Bonfini G., Bonivento W., Borisova E., Bottino B., Boulay M.G., Bunker R., Bussino S., Buzulutskov A., Cadeddu M., Cadoni M., Caminata A., Canci N., Candela A., Cantini C., Caravati M., Cariello M., Carnesecchi F., Castellani A., Castello P., Cavalcante P., Cavazza D., Cavuoti S., Cebrian S., Cela Ruiz J.M., Celano B., Cereseto R., Chashin S., Cheng W., Chepurnov A., Cicalo C., Cifarelli L., Citterio M., Coccetti F., Cocco V., Colocci M., Conde Vilda E., Consiglio L., Cossio F., Covone G., Crivelli P., D'Antone I., D'Incecco M., Da Rocha Rolo M.D., Dadoun O., Daniel M., Davini S., De Cecco S., De Deo M., De Falco A., De Gruttola D., De Guido G., De Rosa G., Dellacasa G., Demontis P., De Pasquale S., Derbin A.V., Devoto A., Eusanio F.D., Di Noto L., Di Pietro G., Di Stefano P., Dionisi C., Dolganov G., Dordei F., Downing M., Edalatfar F., Empl A., Fernandez Diaz M., Filip C., Fiorillo G., Fomenko K., Franceschi A., Franco D., Frolov E., Froudakis G.E., Funicello N., Gabriele F., Gabrieli A., Galbiati C., Garbini M., Garcia Abia P., Gascon Fora D., Gendotti A., Ghiano C., Ghisi A., Giampa P., Giampaolo R.A., Giganti C., Giorgi M.A., Giovanetti G.K., Gligan M.L., Gorchakov O., Grab M., Graciani Diaz R., Grassi M., Grate J.W., Grobov A., Gromov M., Guan M., Guerra M.B.B., Guerzoni M., Gulino M., Haaland R.K., Hackett B.R., Hallin A., Haranczyk M., Harrop B., Hoppe E.W., Horikawa S., Hosseini B., Hubaut F., Humble P., Hungerford E.V., Ianni A., Ilyasov A., Ippolito V., Jillings C., Keeter K., Kendziora C.L., Kochanek I., Kondo K., Kopp G., Korablev D., Korga G., Kubankin A., Kugathasan R., Kuss M., La Commara M., La Delfa L., Lai M., Lebois M., Lehnert B., Levashko N., Li X., Liqiang Q., Lissia M., Lodi G.U., Longo G., Lussana R., Luzzi L., Machado A.A., Machulin I.N., Mandarano A., Manecki S., Mapelli L., Margotti A., Mari S.M., Mariani M., Maricic J., Marinelli M., Marras D., Martinez M., Martinez Rojas A.D., Mascia M., Mason J., Masoni A., McDonald A.B., Messina A., Miletic T., Milincic R., Moggi A., Moioli S., Monroe J., Morrocchi M., Mroz T., Mu W., Muratova V.N., Murphy S., Muscas C., Musico P., Nania R., Napolitano T., Navrer Agasson A., Nessi M., Nikulin I., Nosov V., Nowak J.A., Oleinik A., Oleynikov V., Orsini M., Ortica F., Pagani L., Pallavicini M., Palmas S., Pandola L., Pantic E., Paoloni E., Pazzona F., Peeters S., Pegoraro P.A., Pelczar K., Pellegrini L.A., Pellegrino C., Pelliccia N., Perotti F., Pesudo V., Picciau E., Pietropaolo F., Pocar A., Pollmann T.R., Portaluppi D., Poudel S.S., Pralavorio P., Price D., Radics B., Raffaelli F., Ragusa F., Razeti M., Regenfus C., Renshaw A.L., Rescia S., Rescigno M., Retiere F., Rignanese L.P., Ripoli C., Rivetti A., Rode J., Romani A., Romero L., Rossi N., Rubbia A., Sala P., Salatino P., Samoylov O., Sanchez Garcia E., Sandford E., Sanfilippo S., Sant M., Santone D., Santorelli R., Savarese C., Scapparone E., Schlitzer B., Scioli G., Segreto E., Seifert A., Semenov D.A., Shchagin A., Sheshukov A., Siddhanta S., Simeone M., Singh P.N., Skensved P., Skorokhvatov M.D., Smirnov O., Sobrero G., Sokolov A., Sotnikov A., Stainforth R., Steri A., Stracka S., Strickland V., Suffritti G.B., Sulis S., Suvorov Y., Szelc A.M., Tartaglia R., Testera G., Thorpe T., Tonazzo A., Tosi A., Tuveri M., Unzhakov E.V., Usai G., Vacca A., Vazquez-Jauregui E., Viant T., Viel S., Villa F., Vishneva A., Vogelaar R.B., Wahl J., Walding J.J., Wang H., Wang Y., Westerdale S., Wheadon R.J., Williams R., Wilson J., Wojcik M.M., Wojcik M., Wu S., Xiao X., Yang C., Ye Z., Zuffa M., and Zuzel G.
- Subjects
Physics - Instrumentation and Detectors ,Physics and Astronomy (miscellaneous) ,Physics::Instrumentation and Detectors ,01 natural sciences ,7. Clean energy ,High Energy Physics - Experiment ,High Energy Physics - Experiment (hep-ex) ,darkside ,cmos ,[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex] ,Detectors and Experimental Techniques ,sipm ,physics.ins-det ,Physics ,ESPALHAMENTO ,Bremsstrahlung ,neutrinos ,Noble gas ,Instrumentation and Detectors (physics.ins-det) ,argon ,photoluminescence ,Astrophysics - Instrumentation and Methods for Astrophysics ,physics ,Particle Physics - Experiment ,Astrophysics and Astronomy ,Photomultiplier ,SiPM readout two-phase argon detectors electroluminescence visible near infrared ,FOS: Physical sciences ,chemistry.chemical_element ,lcsh:Astrophysics ,physics, detector, cmos, dark matter, darkside, photoluminescence, sipm, radiation, neutrinos, argon ,Electroluminescence ,dark matter ,Electron avalanche ,Optics ,Silicon photomultiplier ,lcsh:QB460-466 ,0103 physical sciences ,lcsh:Nuclear and particle physics. Atomic energy. Radioactivity ,010306 general physics ,Instrumentation and Methods for Astrophysics (astro-ph.IM) ,Engineering (miscellaneous) ,Scintillation ,Argon ,detector ,hep-ex ,010308 nuclear & particles physics ,business.industry ,radiation ,chemistry ,lcsh:QC770-798 ,SiPM, dual-phase TPC, Darkside-20k ,business ,astro-ph.IM - Abstract
Proportional electroluminescence (EL) in noble gases is used in two-phase detectors for dark matter searches to record (in the gas phase) the ionization signal induced by particle scattering in the liquid phase. The "standard" EL mechanism is considered to be due to noble gas excimer emission in the vacuum ultraviolet (VUV). In addition, there are two alternative mechanisms, producing light in the visible and near infrared (NIR) ranges. The first is due to bremsstrahlung of electrons scattered on neutral atoms ("neutral bremsstrahlung", NBrS). The second, responsible for electron avalanche scintillation in the NIR at higher electric fields, is due to transitions between excited atomic states. In this work, we have for the first time demonstrated two alternative techniques of the optical readout of two-phase argon detectors, in the visible and NIR range, using a silicon photomultiplier matrix and electroluminescence due to either neutral bremsstrahlung or avalanche scintillation. The amplitude yield and position resolution were measured for these readout techniques, which allowed to assess the detection threshold for electron and nuclear recoils in two-phase argon detectors for dark matter searches. To the best of our knowledge, this is the first practical application of the NBrS effect in detection science., Comment: 26 pages, 22 figures, 3 tables
- Published
- 2021
28. Issues related to the research on vitamin K supplementation and bone mineral density
- Author
-
Mary E. D'Alton, Ka Kahe, Suzanne E. Judd, M. Kyla Shea, and Yijia Zhang
- Subjects
Bone mineral ,medicine.medical_specialty ,Nutrition and Dietetics ,Endocrinology ,business.industry ,Internal medicine ,medicine ,Medicine (miscellaneous) ,Vitamin k ,business - Published
- 2021
29. Racial and Ethnic Disparities in Peripartum Hysterectomy Risk and Outcomes
- Author
-
Jean-Ju Sheen, Jason D. Wright, Dena Goffman, Alexander M. Friedman, Timothy Wen, Cynthia Gyamfi-Bannerman, Margaret Bogardus, and Mary E. D'Alton
- Subjects
Adult ,Risk ,Adolescent ,medicine.medical_treatment ,Ethnic group ,Maternal morbidity ,Hysterectomy ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Ethnicity ,Peripartum Period ,medicine ,Humans ,030212 general & internal medicine ,Healthcare Disparities ,Retrospective Studies ,Peripartum hysterectomy ,030219 obstetrics & reproductive medicine ,business.industry ,Pregnancy Outcome ,Obstetrics and Gynecology ,United States ,Confidence interval ,Cross-Sectional Studies ,Maternal Mortality ,Increased risk ,Relative risk ,Pediatrics, Perinatology and Child Health ,Regression Analysis ,Severe morbidity ,Female ,business ,Demography - Abstract
This study aimed to determine whether race and ethnicity contribute to risks associated with peripartum hysterectomy.This retrospective cross-sectional study utilized the 2000-2014 Nationwide Inpatient Sample to analyze risk of peripartum hysterectomy and associated severe maternal morbidity, mortality, surgical injury, reoperation, surgical-site complications, and mortality by maternal race and ethnicity. Race and ethnicity were categorized as non-Hispanic white, non-Hispanic black, Hispanic, other, and unknown. Multivariable log-linear regression models including patient, clinical, and hospital risk factors were performed with adjusted risk ratios (aRRs) and 95% confidence intervals (CIs).Of 59,854,731 delivery hospitalizations, there were 45,369 peripartum hysterectomies (7.6 per thousand). Of these, 37.8% occurred among non-Hispanic white, 13.9% among non-Hispanic black, and 22.8% among Hispanic women. In adjusted analyses, non-Hispanic black (aRR: 1.21, 95% CI: 1.17-1.29) and Hispanic women (aRR: 1.25, 95% CI: 1.22-1.29) were at increased risk of hysterectomy compared with non-Hispanic white women. Risk for severe morbidity was increased for non-Hispanic black (aRR: 1.25, 95% CI: 1.19-1.33), but not for Hispanic (aRR: 1.02, 95% CI: 0.97-1.07) women. Between these three groups, risk for intraoperative complications was highest among non-Hispanic white women, risk for reoperation was highest among Hispanic women, and risk for surgical-site complications was highest among non-Hispanic black women. Evaluating maternal mortality, non-Hispanic black women (RR: 3.83, 95% CI: 2.65-5.53) and Hispanic women (RR: 2.49, 95% CI: 1.74-3.59) were at higher risk than non-Hispanic white women.Peripartum hysterectomy and related complications other than death differed modestly by race. In comparison, mortality differentials were large supporting that differential risk for death in the setting of this high-risk scenario may be an important cause of disparities.· Peripartum hysterectomy and related complications differed modestly by race.. · Mortality differentials in the setting of peripartum hysterectomy were large.. · Failure to rescue may be an important cause of peripartum hysterectomy disparities..
- Published
- 2021
30. Talking about recommended age or fewer doses: what motivates HPV vaccination timeliness?
- Author
-
William A. Calo, Marjorie A. Margolis, Melissa B. Gilkey, Parth D. Shah, Susan Alton Dailey, and Noel T. Brewer
- Subjects
Parents ,Pharmacology ,Health Knowledge, Attitudes, Practice ,Pediatrics ,medicine.medical_specialty ,Adolescent ,business.industry ,Papillomavirus Infections ,Vaccination ,030231 tropical medicine ,Immunology ,Short Report ,Hpv vaccination ,Human papillomavirus vaccine ,03 medical and health sciences ,0302 clinical medicine ,Humans ,Immunology and Allergy ,Medicine ,Papillomavirus Vaccines ,030212 general & internal medicine ,Child ,business ,Adolescent health - Abstract
HPV vaccination is recommended for U.S. adolescents at ages 11–12 and requires two versus three doses if the series is started before age 15. We evaluated how talking about recommended age or fewer doses motivates on-time HPV vaccination. Our national, online experiment randomized 1,263 parents of adolescents to view one of three messages about HPV vaccination recommendations or no message. Messages framed guidelines as recommending: vaccination at age 11–12; fewer doses for those who start vaccination at age 11–12; or, fewer doses for those who start vaccination before age 15. We then assessed parents’ preferred age for HPV vaccination, categorizing preferences of ≤12 years as on-time. Parents who viewed “at age 11–12” versus no message more often preferred on-time HPV vaccination (63% vs. 43%, p .05). Parents who viewed “fewer doses before age 15” less often preferred on-time HPV vaccination (39%, p
- Published
- 2021
31. Hospital Admissions from the Emergency Department and Subsequent Critical Care Interventions for Influenza during Pregnancy
- Author
-
Nicole Krenitsky, Stephanie Cham, Kartik K. Venkatesh, William J. Mack, Frank J. Attenello, Alexander M. Friedman, Timothy Wen, and Mary E. D'Alton
- Subjects
education.field_of_study ,medicine.medical_specialty ,Pregnancy ,030219 obstetrics & reproductive medicine ,business.industry ,Public health ,Population ,Psychological intervention ,Obstetrics and Gynecology ,Emergency department ,medicine.disease ,Intensive care unit ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,Relative risk ,Pediatrics, Perinatology and Child Health ,Emergency medicine ,medicine ,030212 general & internal medicine ,education ,business ,Disease burden - Abstract
OBJECTIVE The objectives of this study were to determine (1) whether obstetrical patients were more likely to be admitted from the emergency department (ED) for influenza compared with nonpregnant women, and (2) require critical care interventions once admitted. STUDY DESIGN Using data from the 2006 to 2011 Nationwide Emergency Department Sample, ED encounters for influenza for women aged 15 to 54 years without underlying chronic medical conditions were identified. Women were categorized as pregnant or nonpregnant using billing codes. Multivariable log linear models were fit to evaluate the relative risk of admission from the ED and the risk of intensive care unit (ICU)-level interventions including mechanical ventilation and central monitoring with pregnancy status as the exposure of interest. Measures of association were described with adjusted risk ratios (aRRs) with 95% confidence intervals (CIs). RESULTS We identified 15.9 million ED encounters for influenza of which 4% occurred among pregnant women. Pregnant patients with influenza were nearly three times as likely to be admitted as nonpregnant patients (aRR = 2.99, 95% CI: 2.94, 3.05). Once admitted, obstetric patients were at 72% higher risk of ICU-level interventions (aRR = 1.72, 95% CI: 1.61, 1.84). Of pregnant women admitted from the ED, 9.3% required ICU-level interventions such as mechanical ventilation or central monitoring. Older patients and those with Medicare were also at high risk of admission and ICU-level interventions (p
- Published
- 2021
32. Clinical and Demographic Risk Factors for COVID-19 during Delivery Hospitalizations in New York City
- Author
-
Ka Kahe, Yongmei Huang, Bruce Feinberg, Alexander M. Friedman, Anna P. Staniczenko, Desmond Sutton, Amma D. Ntoso, Lynn L. Simpson, Maria Andrikopoulou, Dena Goffman, Russell S. Miller, Jean-Ju Sheen, Karin Fuchs, James A. Lasky, Ruth Landau, Cynthia Gyamfi-Bannerman, Timothy Wen, Mary E. D'Alton, and Alexis Panzer
- Subjects
Adult ,medicine.medical_specialty ,Fever ,Chest pain ,Logistic regression ,Cohort Studies ,Obesity, Maternal ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Residence Characteristics ,Risk Factors ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Pregnancy Complications, Infectious ,Young adult ,Retrospective Studies ,030219 obstetrics & reproductive medicine ,Cesarean Section ,SARS-CoV-2 ,Vaginal delivery ,business.industry ,COVID-19 ,Obstetrics and Gynecology ,Retrospective cohort study ,Pneumonia ,Length of Stay ,Delivery, Obstetric ,medicine.disease ,Hospitalization ,Chorioamnionitis ,Logistic Models ,Quartile ,Carrier State ,Pediatrics, Perinatology and Child Health ,Female ,New York City ,medicine.symptom ,business ,Maternal Age ,Cohort study - Abstract
Objective This study was aimed to review 4 weeks of universal novel coronavirus disease 2019 (COVID-19) screening among delivery hospitalizations, at two hospitals in March and April 2020 in New York City, to compare outcomes between patients based on COVID-19 status and to determine whether demographic risk factors and symptoms predicted screening positive for COVID-19. Study Design This retrospective cohort study evaluated all patients admitted for delivery from March 22 to April 18, 2020, at two New York City hospitals. Obstetrical and neonatal outcomes were collected. The relationship between COVID-19 and demographic, clinical, and maternal and neonatal outcome data was evaluated. Demographic data included the number of COVID-19 cases ascertained by ZIP code of residence. Adjusted logistic regression models were performed to determine predictability of demographic risk factors for COVID-19. Results Of 454 women delivered, 79 (17%) had COVID-19. Of those, 27.9% (n = 22) had symptoms such as cough (13.9%), fever (10.1%), chest pain (5.1%), and myalgia (5.1%). While women with COVID-19 were more likely to live in the ZIP codes quartile with the most cases (47 vs. 41%) and less likely to live in the ZIP code quartile with the fewest cases (6 vs. 14%), these comparisons were not statistically significant (p = 0.18). Women with COVID-19 were less likely to have a vaginal delivery (55.2 vs. 51.9%, p = 0.04) and had a significantly longer postpartum length of stay with cesarean (2.00 vs. 2.67days, p Conclusion COVID-19 symptoms were present in a minority of COVID-19-positive women admitted for delivery. Significant differences in obstetrical outcomes were found. While demographic risk factors demonstrated acceptable discrimination, risk prediction does not capture a significant portion of COVID-19-positive patients. Key Points
- Published
- 2021
33. Longitudinal Risk Adjustment for Maternal End-Organ Injury and Death
- Author
-
Nicole Krenitsky, Timothy Wen, Jason D. Wright, Alexander M. Friedman, Yongmei Huang, Mary E. D'Alton, and Samsiya Ona
- Subjects
medicine.medical_specialty ,030219 obstetrics & reproductive medicine ,business.industry ,Postpartum Period ,Obstetrics and Gynecology ,Risk adjustment ,medicine.disease ,Comorbidity ,United States ,03 medical and health sciences ,0302 clinical medicine ,Healthcare utilization ,Pregnancy ,Pediatrics, Perinatology and Child Health ,Emergency medicine ,Ethnicity ,Humans ,Medicine ,Female ,Risk Adjustment ,Obesity ,030212 general & internal medicine ,business ,Retrospective Studies - Abstract
To determine whether adjusting for healthcare utilization and comorbidity diagnosed in the year before delivery improves the prediction of adverse maternal outcomes. The Truven Health MarketScan database was used to determine whether healthcare utilization and comorbidity diagnosed in the year before pregnancy improved prediction of acute organ injury or death during the delivery hospitalization through 30 days postpartum in this retrospective cohort study. In an initial model, we analyzed the risk for adverse outcomes controlling for underlying comorbidity, obesity, and demographic risk factors present during pregnancy. Subsequent models included diagnoses from the year before pregnancy as well as whether patients had emergency department encounters, inpatient hospitalizations, or received medications from a pharmacy. We compared risk estimates and whether prediction of acute organ injury or death improved with data from the year before pregnancy. Unadjusted and adjusted log-linear regression models were performed to demonstrate the association between exposures and outcomes with unadjusted (RR) and adjusted risk ratios (aRR) with 95% CIs as measures of effects. Logistic regression was performed to calculate the c-statistic of the adjusted models. Separate analyses were performed for patients with Medicaid and commercial insurance. An analysis of Medicaid patients by maternal race and ethnicity was performed to determine if diagnoses and utilization before pregnancy accounted for maternal disparities. A total of 740,002 patients were analyzed in this study. In unadjusted analyses of patients with commercial insurance, ≥2 compared to 0 emergency department encounters (RR = 1.82, 95% CI = 1.61, 2.07), ≥2 compared to 0 inpatient hospitalizations (RR = 4.43, 95% CI = 3.20, 6.13), and receipt of medications from ≥5 prescription groups compared to no prescriptions (RR = 1.97, 95% CI = 1.74, 2.24) were all associated with increased risk for acute organ injury or death. Higher underlying comorbidity and obesity were also associated with increased risk. These risks were attenuated in adjusted analyses but retained significance. Risk estimates were similar for patients with Medicaid insurance with the exception of receipt of medications from ≥5 prescription groups which was non-significant in adjusted analyses (aRR = 1.12, 95% CI = 0.90, 1.40). C-statistics from logistic regression models were similar for models with and without pre-pregnancy data. When race was added to the adjusted models, risk among black women in the adjusted models did not differ significantly from the unadjusted estimate. ED encounters and inpatient admissions the year before pregnancy were associated with increased risk of adverse maternal outcomes. However, adding these risk factors to adjusted models did not meaningfully improve the amount of variance accounted for. Further research is indicated to determine to what degree longitudinal care quality is associated with maternal risk.
- Published
- 2021
34. Optimal portfolios of blood safety interventions: test, defer or modify?
- Author
-
Brian Custer, Margaret L. Brandeau, and W. Alton Russell
- Subjects
Emerging technologies ,business.industry ,Cost effectiveness ,education ,Psychological intervention ,Medicine (miscellaneous) ,Health informatics ,Identification (information) ,Risk analysis (engineering) ,General Health Professions ,Leverage (statistics) ,Portfolio ,business ,Deferral - Abstract
A safe supply of blood for transfusion is a critical component of the healthcare system in all countries. Most health systems manage the risk of transfusion-transmissible infections (TTIs) through a portfolio of blood safety interventions. These portfolios must be updated periodically to reflect shifting epidemiological conditions, emerging infectious diseases, and new technologies. However, the number of available blood safety portfolios grows exponentially with the number of available interventions, making it impossible for policymakers to evaluate all feasible portfolios without the assistance of a computer model. We develop a novel optimization model for evaluating blood safety portfolios that enables systematic comparison of all feasible portfolios of deferral, testing, and modification interventions to identify the portfolio that is preferred from a cost-utility perspective. We present structural properties that reduce the state space and required computation time in certain cases, and we develop a linear approximation of the model. We apply the model to retrospectively evaluate U.S. blood safety policies for Zika and West Nile virus for the years 2017, 2018, and 2019, defining donor groups based on season and geography. We leverage structural properties to efficiently find an optimal solution. We find that the optimal portfolio varies geographically, seasonally, and over time. Additionally, we show that for this problem the approximated model yields the same optimal solution as the exact model. Our method enables systematic identification of the optimal blood safety portfolio in any setting and any time period, thereby supporting decision makers in efforts to ensure the safety of the blood supply.
- Published
- 2021
35. Modernizing the Analytical Chemistry Laboratory: The Design and Implementation of a Modular Protein-Centered Course
- Author
-
Dakota G. Hawkins, Kylie C. Lawrence, Megan C. Connor, Alton C. Gayton, Caroline R. Stanton, Amanda L. Smythers, Leslie M. Hicks, and Megan M. Ford
- Subjects
010405 organic chemistry ,business.industry ,media_common.quotation_subject ,05 social sciences ,050301 education ,Analytical Chemistry (journal) ,General Chemistry ,Modular design ,01 natural sciences ,0104 chemical sciences ,Education ,Personalization ,Presentation ,Identification (information) ,Engineering management ,Undergraduate research ,ComputingMilieux_COMPUTERSANDEDUCATION ,Instrumentation (computer programming) ,business ,0503 education ,Curriculum ,media_common - Abstract
Course-based undergraduate research experiences (CUREs) integrate authentic research into undergraduate chemistry laboratories, introducing students to research while simultaneously reinforcing fundamental concepts. Despite their ubiquitous nature in bioanalytical research, few CUREs have been published applying the fundamental techniques of separations, spectroscopy, quantification, and mass spectrometry. To engage students in learning these increasingly essential bioanalytical techniques, we designed and implemented a semester-long project-based course centered around the purification, quantification, and identification of heterologously expressed proteins in five succinct and adaptable modules. Instructors can use these modules to form the foundation of a CURE specific to their research interests. The extensive commercial availability of plasmids for transformation combined with the modular approach to laboratory experiments enables convenient customization to accommodate diverse research goals. Instructors can tailor the modules to meet the curricular requirements and instrumentation capabilities of their institutions and can easily extend the research goals to incorporate more specialized analytical techniques, as needed. Through the implementation of the five modules, students apply the fundaments of acid–base chemistry, statistics, quantification strategies, spectrophotometry, separations, and mass spectrometry, thus covering the material required in most undergraduate introductory analytical courses. Instructors can then use these modules as a backbone to support student-led discovery-based investigations for the remainder of the course. Students demonstrate their understanding through the completion of a comprehensive, publication-style laboratory report as well as a poster presentation at a university-wide undergraduate research symposium. Since first offering this course in 2016, student evaluations have been exceedingly positive, with over 75% of students indicating that the course both increased their scientific skills as well as their confidence in their ability to succeed in further science courses. Furthermore, 22% of students reported they were “much more” or “extremely more” likely to enroll in a Ph.D. program in science, math, or engineering following the courses, emphasizing the impact that project-based laboratories can have on undergraduate chemists’ career trajectories.
- Published
- 2021
36. Willingness to Use Cannabis for Gynecological Conditions: A National Survey
- Author
-
Blair G. Darney, Alyssa Covelli Colwill, Katie Alton, Sara McCrimmon, Leo Han, and Jeffrey T. Jensen
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Medical Marijuana ,General Medicine ,biology.organism_classification ,United States ,03 medical and health sciences ,Logistic Models ,0302 clinical medicine ,Willingness to use ,Surveys and Questionnaires ,Family medicine ,Humans ,Medicine ,Female ,030212 general & internal medicine ,Cannabis ,business ,health care economics and organizations ,030217 neurology & neurosurgery - Abstract
Objective: Expanded legal access to cannabis in the United States has led to its increased use for treating medical conditions. We assessed the use of and attitudes toward cannabis for treating gyn...
- Published
- 2021
37. Obstetric Inpatient and Ultrasound Clinical Personnel Absences during the COVID-19 Pandemic in New York City
- Author
-
Russell S. Miller, Janice Aubey, Dena Goffman, Lynn L. Simpson, Karin Fuchs, Natali E. Valderrama, Kenya E. Robinson, Cynthia Gyamfi-Bannerman, Timothy Wen, Jessica Spiegelman, Noelia Zork, Alexander M. Friedman, Jean-Ju Sheen, Mary E. D'Alton, and Clara Bertozzi-Villa
- Subjects
Inpatients ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Staffing ,Columbia university ,MEDLINE ,COVID-19 ,Obstetrics and Gynecology ,Retrospective cohort study ,Test (assessment) ,Pregnancy ,Family medicine ,Pediatrics, Perinatology and Child Health ,Pandemic ,medicine ,Humans ,Female ,New York City ,Child ,business ,Pandemics ,Obstetrical nursing ,Retrospective Studies - Abstract
Objective To review obstetric personnel absences at a hospital during the initial peak of coronavirus disease 2019 (COVID-19) infection risk in New York City from March 25 to April 21, 2020. Study Design This retrospective study evaluated absences at Morgan Stanley Children's Hospital. Clinical absences for (1) Columbia University ultrasonographers, (2) inpatient nurses, (3) labor and delivery operating room (OR) technicians, (4) inpatient obstetric nurse assistants, and (5) attending physicians providing inpatient obstetric services were analyzed. Causes of absences were analyzed and classified as illness, vacation and holidays, leave, and other causes. Categorical variables were compared with the chi-square test or Fisher's exact test. Results For nurses, absences accounted for 1,052 nursing workdays in 2020 (17.2% of all workdays) compared with 670 (11.1%) workdays in 2019 (p Conclusion COVID-19 outbreak surge planning represents a major operational issue for medical specialties such as critical care due to increased clinical volume. Findings from this analysis suggest it is prudent to devise backup staffing plans. Key Points
- Published
- 2021
38. Avoidance of CNI and steroids using belatacept—Results of the Clinical Trials in Organ Transplantation 16 trial
- Author
-
Tara K. Sigdel, Christian P. Larsen, Kenneth A. Newell, Yvonne Morrison, Roslyn B. Mannon, Minnie M. Sarwal, Natasha Watson, Nancy D. Bridges, Alton B. Farris, Mark A. Robien, Peter G. Stock, Aneesh K. Mehta, and Brian Armstrong
- Subjects
Graft Rejection ,Oncology ,Kidney Disease ,medicine.medical_treatment ,immunosuppression/immune modulation ,030230 surgery ,Medical and Health Sciences ,Organ transplantation ,law.invention ,0302 clinical medicine ,Maintenance therapy ,Randomized controlled trial ,law ,fusion proteins and monoclonal antibodies ,Immunology and Allergy ,Pharmacology (medical) ,kidney transplantation / nephrology ,belatacept ,immunosuppression ,Graft Survival ,clinical trial ,Immunosuppression ,practice ,costimulation ,6.1 Pharmaceuticals ,mediated ,Steroids ,rejection ,Immunosuppressive Agents ,medicine.drug ,medicine.medical_specialty ,Clinical Trials and Supportive Activities ,Renal and urogenital ,nephrology ,kidney transplantation ,clinical research/practice ,Belatacept ,Article ,immunosuppressant ‐ ,Abatacept ,03 medical and health sciences ,Rare Diseases ,Clinical Research ,Internal medicine ,T cell– ,medicine ,Transplantation ,immune modulation ,business.industry ,Evaluation of treatments and therapeutic interventions ,T cell-mediated [rejection] ,Organ Transplantation ,Kidney Transplantation ,Tacrolimus ,Clinical trial ,Calcineurin ,belatacept [immunosuppressant - fusion proteins and monoclonal antibodies] ,Surgery ,business - Abstract
Immunosuppression devoid of corticosteroids has been investigated to avoid long-term comorbidities. Likewise, alternatives to calcineurin inhibitors have been investigated as a strategy to improve long-term kidney function following transplanion. Costimulatory blockade strategies that include corticosteroids have recently shown promise, despite their higher rates of early acute rejection. We designed a randomized clinical trial utilizing depletional induction therapy to mitigate early rejection risk while limiting calcineurin inhibitors and corticosteroids. This trial, Clinical Trials in Organ Transplantation 16 (CTOT-16), sought to evaluate novel belatacept-based strategies employing tacrolimus and corticosteroid avoidance. Sixty-nine kidney transplant recipients were randomized from 4 US transplant centers comparing a control group of with rabbit antithymocyte globulin (rATG) induction, rapid steroid taper, and maintenance mycophenolate and tacrolimus, to 2 arms using maintenance belatacept. There were no graft losses but there were 2 deaths in the control group. However, the trial was halted early because of rejection in the belatacept treatment groups. Serious adverse events were similar across groups. Although rejection was not uniform in the belatacept maintenance therapy groups, the frequency of rejection limits the practical implementation of this strategy to avoid both calcineurin inhibitors and corticosteroids at this time.
- Published
- 2020
39. Cardiovascular Care for Pregnant Women With Cardiovascular Disease
- Author
-
Anita LaSala, Ella Magun, Mary E. D'Alton, Sarah Noble, Carol A. Waksmonski, Jennifer Haythe, and Ersilia M. DeFilippis
- Subjects
Adult ,Gestational hypertension ,medicine.medical_specialty ,Pregnancy Complications, Cardiovascular ,Population ,030204 cardiovascular system & hematology ,Patient Readmission ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Interquartile range ,medicine ,Humans ,030212 general & internal medicine ,education ,Retrospective Studies ,education.field_of_study ,business.industry ,Obstetrics ,Pregnancy Outcome ,Gestational age ,Prenatal Care ,medicine.disease ,Gestational diabetes ,Cardiovascular Diseases ,Female ,New York City ,Maternal death ,Pregnant Women ,Cardiology and Cardiovascular Medicine ,Live birth ,business - Abstract
Background Cardio-obstetrics refers to a team-based approach to maternal care that includes multidisciplinary collaboration among maternal fetal medicine, cardiology, and others. Objectives This study sought to describe clinical characteristics, maternal and fetal outcomes, and cardiovascular readmissions in a cohort of pregnant women with underlying cardiovascular disease (CVD) followed by a cardio-obstetrics team. Methods We identified patients evaluated by our cardio-obstetrics team from January 1, 2010, through December 31, 2019, at a quaternary care hospital in New York City. Information was collected regarding demographics, comorbidities, underlying CVD, medications, maternal and fetal outcomes, and cardiovascular readmissions. Each patient was assigned a Cardiac Disease in Pregnancy (CARPREG) II score based on her clinical characteristics and underlying CVD. Results During the study period, 306 pregnant women (median age 29 years, 52.9% Hispanic or Latino) with CVD were seen. Most women (74.2%) were insured through Medicaid. The most common forms of CVD included arrhythmia (n = 88, 28.8%), congenital heart disease (n = 72, 23.5%), and cardiomyopathy (n = 72, 23.5%). The median CARPREG II score was 3; 130 patients (42.5%) had a CARPREG II score ≥4. Gestational diabetes occurred in 11.4%, gestational hypertension in 9.5%, and preeclampsia in 12.1% of women. Intensive care unit admission was required for 27 patients (8.8%) during delivery. Median gestational age for delivery was 38 weeks (interquartile range: 37 to 39). Live birth occurred in 98% of pregnancies. One maternal death occurred within a year of delivery in a woman with Eisenmenger syndrome. Following delivery, 30-day readmission rate was 2% and the rate of readmission from 30 to 90 days postpartum was 4.6%. Median follow-up was 2.6 years. Conclusions In a population of primarily Medicaid-insured pregnant women managed by a cardio-obstetrics team, maternal outcomes were encouraging and readmission rates following delivery were low. Prospective studies are needed to evaluate the impact of cardio-obstetric models of care on maternal outcomes.
- Published
- 2020
40. Baseline creatinine determination method impacts association between acute kidney injury and clinical outcomes
- Author
-
W. Alton Russell, David Scheinker, and Scott M. Sutherland
- Subjects
Nephrology ,Creatinine ,medicine.medical_specialty ,Inpatient mortality ,urogenital system ,business.industry ,030232 urology & nephrology ,Acute kidney injury ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,medicine.disease ,female genital diseases and pregnancy complications ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,Internal medicine ,Pediatrics, Perinatology and Child Health ,Epidemiology ,Medicine ,business ,Estimation methods ,Kidney disease - Abstract
Current consensus definition for acute kidney injury (AKI) does not specify how baseline serum creatinine should be determined. We assessed how baseline determination impacted AKI incidence and association between AKI and clinical outcomes. We retrospectively applied empirical (measured serum creatinine) and imputed (age/height) baseline estimation methods to pediatric patients discharged between 2014 and 2019 from an academic hospital. Using each method, we estimated AKI incidence and assessed area under ROC curve (AUROC) for AKI as a predictor of three clinical outcomes: application of AKI billing code (proxy for more clinically overt disease), inpatient mortality, and post-hospitalization chronic kidney disease. Incidence was highly variable across baseline methods (12.2–26.7%). Incidence was highest when lowest pre-admission creatinine was used if available and Schwartz bedside equation was used to impute one otherwise. AKI was more predictive of application of an AKI billing code when baseline was imputed universally, regardless of pre-admission values (AUROC 80.7–84.9%) than with any empirical approach (AUROC 64.5–76.6%). AKI was predictive of post-hospitalization CKD when using universal imputation baseline methods (AUROC 67.0–74.6%); AKI was not strongly predictive of post-hospitalization CKD when using empirical baseline methods (AUROC 46.4–58.5%). Baseline determination method did not affect the association between AKI and inpatient mortality. Method of baseline determination influences AKI incidence and association between AKI and clinical outcomes, illustrating the need for standard criteria. Imputing baseline for all patients, even when preadmission creatinine is available, may identify a more clinically relevant subset of the disease.
- Published
- 2020
41. Mindfulness-based cognitive therapy as a clinical intervention with psoriasis patients through the lens of the clinically modified Buddhist psychological model: a qualitative study
- Author
-
Alan Maddock, Brian Kirby, David Hevey, and Paul D’Alton
- Subjects
050103 clinical psychology ,Coping (psychology) ,Psychotherapist ,Mindfulness ,business.industry ,fungi ,05 social sciences ,food and beverages ,050109 social psychology ,medicine.disease ,Psychiatry and Mental health ,Clinical Psychology ,Psoriasis ,Intervention (counseling) ,Psoriasis patient ,Medicine ,0501 psychology and cognitive sciences ,business ,Cognitive appraisal ,Mindfulness-based cognitive therapy ,Qualitative research - Abstract
Coping with a chronic illness such as psoriasis can be very stressful experience for patients. A psoriasis patient’s cognitive appraisal of their condition, definition of adaptive tasks, and select...
- Published
- 2020
42. Breast cancer subtypes in Australian Chinese women
- Author
-
Michael Law, Alton Hong, Jonathan Chua, and Michael Cheng
- Subjects
China ,medicine.medical_specialty ,Younger age ,Breast Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Asian People ,Internal medicine ,medicine ,Humans ,Pathological ,Breast surgeons ,business.industry ,Incidence ,Incidence (epidemiology) ,Significant difference ,Australia ,General Medicine ,Luminal a ,medicine.disease ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,Surgery ,Breast carcinoma ,business - Abstract
BACKGROUND It has been suggested that Chinese patients with breast cancer present at a younger age compared to the general Australian population, with tumour pathological characteristics that carry less favourable outcomes. This study was aimed to investigate if a substantial difference in breast cancer subtypes exists between the Australian Chinese population and the general Australian population. METHODS All patients with breast cancer treated by two of the authors (consultant breast surgeons) at Eastern Health, Victoria between 2010 and 2016 were identified through the BreastSurgANZ Quality Audit database. Australian Chinese patients were further identified through outpatient records and registration information. Medical histories were examined to obtain patient demographics, tumour characteristics and outcome. Patient and tumour characteristics between the Australian Chinese population were then compared to the general Australian population. RESULTS A total of 97 Australian Chinese patients with breast cancer were identified out of 582 patients. Mean age at diagnosis was 56.7 years, approximately 6 years younger than the general Australian population. There was a statistically significant difference in incidence of Luminal A tumours with 25 patients (25.77%) from the Chinese group affected compared to 310 patients (63.92%) from the general group (P
- Published
- 2020
43. Validation of MRI‐VLFF for the non‐invasive measurement of steatosis in children
- Author
-
Stephen F. Simoneaux, Alvin J. Freeman, Rebecca Cleeton, Miriam B. Vos, Eduardo Castillo‐Leon, Jack Knight-Scott, Jun Kong, Albert Hernandez, Jennifer K. Frediani, Michael J. House, Timothy G. St. Pierre, and Alton B. Farris
- Subjects
medicine.medical_specialty ,business.industry ,Non invasive ,Medicine ,Radiology ,Steatosis ,business ,medicine.disease - Published
- 2020
44. Measurement of hemorrhage-related severe maternal morbidity with billing versus electronic medical record data
- Author
-
Mary E. D'Alton, Jean-Ju Sheen, Robert A. Green, Alan Kessler, Matthew A. Oberhardt, David K. Vawdrey, Alexander M. Friedman, and Dena Goffman
- Subjects
Male ,Hemorrhage ,Maternal morbidity ,Article ,03 medical and health sciences ,0302 clinical medicine ,International Classification of Diseases ,Pregnancy ,Electronic Health Records ,Humans ,Medicine ,030212 general & internal medicine ,030219 obstetrics & reproductive medicine ,business.industry ,Electronic medical record ,Fibrinogen ,Obstetrics and Gynecology ,Puerperal Disorders ,Disseminated Intravascular Coagulation ,medicine.disease ,Dacarbazine ,Pediatrics, Perinatology and Child Health ,Female ,Medical emergency ,business ,Quality assurance - Abstract
OBJECTIVE: Measurement of obstetric hemorrhage-related morbidity is important for quality assurance purposes but presents logistical challenges in large populations. Billing codes are typically used to track severe maternal morbidity but may be of suboptimal validity. The objective of this study was to evaluate validity of billing code diagnoses for hemorrhage-related morbidity compared to data obtained from the electronic medical record. STUDY DESIGN: Deliveries occurring between July 2014 and July 2017 from three hospitals within a single system were analyzed. Three outcomes related to obstetric hemorrhage that are part of the Centers for Disease Control and Prevention definition of severe maternal morbidity (SMM) were evaluated: (i) transfusion, (ii) disseminated intravascular coagulation (DIC), and (iii) acute renal failure (ARF). ICD-9-CM and ICD-10-CM for these conditions were ascertained and compared to blood bank records and laboratory values. Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) with 95% confidence intervals (CI) were calculated. Ancillary analyses were performed comparing codes and outcomes between hospitals and comparing ICD-9-CM to ICD-10-CM codes. Comparisons of categorical variables were performed with the chi-squared test. T-tests were used to compare continuous outcomes. RESULTS: 35,518 deliveries were analyzed. 786 women underwent transfusion, 168 had serum creatinine ≥1.2mg/dL, and 99, 40, and 16 had fibrinogen ≤200, ≤150, and ≤100 mg/dL, respectively. Transfusion codes were 65% sensitive (95% CI 62%-69%) with a 91% PPV (89%-94%) for blood bank records of transfusion. DIC codes were 22% sensitive (95% CI 15%-32%) for a fibrinogen cutoff of ≤200mg/dL with 15% PPV (95% CI 10%-22%). Sensitivity for ARF was 33% (95% CI 26%-41%) for a creatinine of 1.2mg/dL with a PPV of 63% (95% CI 52%-73%). Sensitivity of ICD-9-CM for transfusion was significantly higher than ICD-10-CM (81%, 95% CI 76%-86% versus 56%, 95% CI 51%-60%, p
- Published
- 2020
45. Decreased Hepatocyte Autophagy Leads to Synergistic IL‐1β and TNF Mouse Liver Injury and Inflammation
- Author
-
Yunshan Liu, Enpeng Zhao, Francesca Cingolani, Yang Shen, Mark J. Czaja, Shoaib Ahmad Malik, Jing Wen, Reben Raeman, Alton B. Farris, Muhammad Amir, and Pradeep Kumar
- Subjects
Male ,0301 basic medicine ,Programmed cell death ,Necrosis ,Interleukin-1beta ,ATG5 ,Inflammation ,Article ,Proinflammatory cytokine ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Autophagy ,medicine ,Animals ,Cells, Cultured ,Liver injury ,Hepatology ,Tumor Necrosis Factor-alpha ,business.industry ,Liver Diseases ,medicine.disease ,Mice, Inbred C57BL ,030104 developmental biology ,Liver ,Hepatocytes ,Cancer research ,Female ,030211 gastroenterology & hepatology ,Tumor necrosis factor alpha ,medicine.symptom ,business - Abstract
Background and aims The proinflammatory cytokine IL-1β has been implicated in the pathophysiology of nonalcoholic and alcoholic steatohepatitis. How IL-1β promotes liver injury in these diseases is unclear, as no IL-1β receptor-linked death pathway has been identified. Autophagy functions in hepatocyte resistance to injury and death, and findings of decreased hepatic autophagy in many liver diseases suggest a role for impaired autophagy in disease pathogenesis. Recent findings that autophagy blocks mouse liver injury from lipopolysaccharide led to an examination of autophagy's function in hepatotoxicity from proinflammatory cytokines. Approach and results AML12 cells with decreased autophagy from a lentiviral autophagy-related 5 (Atg5) knockdown were resistant to toxicity from TNF, but sensitized to death from IL-1β, which was markedly amplified by TNF co-treatment. IL-1β/TNF death was necrosis by trypan blue and propidium iodide positivity, absence of mitochondrial death pathway and caspase activation, and failure of a caspase inhibitor or necrostatin-1s to prevent death. IL-1β/TNF depleted autophagy-deficient cells of ATP, and ATP depletion and cell death were prevented by supplementation with the energy substrate pyruvate or oleate. Pharmacological inhibitors and genetic knockdown studies demonstrated that IL-1β/TNF-induced necrosis resulted from lysosomal permeabilization and release of cathepsins B and L in autophagy-deficient cells. Mice with a tamoxifen-inducible, hepatocyte-specific Atg5 knockout were similarly sensitized to cathepsin-dependent hepatocellular injury and death from IL-1β/TNF in combination, but neither IL-1β nor TNF alone. Knockout mice had increased hepatic inflammation, and IL-1β/TNF-treated, autophagy-deficient AML12 cells secreted exosomes with proinflammatory damage-associated molecular patterns. Conclusions The findings delineate mechanisms by which decreased hepatocyte autophagy promotes IL-1β/TNF-induced necrosis from impaired energy homeostasis and lysosomal permeabilization and inflammation through the secretion of exosomal damage-associated molecular patterns.
- Published
- 2020
46. Characteristics and Outcomes of 241 Births to Women With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection at Five New York City Medical Centers
- Author
-
David L. Keefe, Meghan Proehl, Lynn L. Simpson, Joanne Stone, Meghana Limaye, Ashley S. Roman, Rodney L. Wright, Lisa Nathan, Christina A. Penfield, Bijan Khaksari, William Schweizer, Dena Goffman, Karina Avila, Siobhan M. Dolan, Fabiano Heitor, Michael Brodman, Rasha Khoury, Sharmila K. Makhija, Melissa Fazzari, Calvin Lambert, Cynthia Gyamfi-Bannerman, Lauren Ferrara, Desmond Sutton, Mary E. D'Alton, Brian Wagner, Chelsea DeBolt, Angela Bianco, Johanna Monro, and Peter S. Bernstein
- Subjects
Adult ,Pediatrics ,medicine.medical_specialty ,Pneumonia, Viral ,Asymptomatic ,law.invention ,Birth rate ,Betacoronavirus ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Risk Factors ,law ,Obstetrics and Gynaecology ,Humans ,Medicine ,Obesity ,Prospective Studies ,030212 general & internal medicine ,Pregnancy Complications, Infectious ,Prospective cohort study ,Pandemics ,030219 obstetrics & reproductive medicine ,Cesarean Section ,SARS-CoV-2 ,business.industry ,Infant, Newborn ,Pregnancy Outcome ,COVID-19 ,Obstetrics and Gynecology ,medicine.disease ,Intensive care unit ,Hospitalization ,Pneumonia ,Cohort ,Premature Birth ,Female ,New York City ,medicine.symptom ,Coronavirus Infections ,business ,Body mass index - Abstract
Objective To describe the characteristics and birth outcomes of women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as community spread in New York City was detected in March 2020. Methods We performed a prospective cohort study of pregnant women with laboratory-confirmed SARS-CoV-2 infection who gave birth from March 13 to April 12, 2020, identified at five New York City medical centers. Demographic and clinical data from delivery hospitalization records were collected, and follow-up was completed on April 20, 2020. Results Among this cohort (241 women), using evolving criteria for testing, 61.4% of women were asymptomatic for coronavirus disease 2019 (COVID-19) at the time of admission. Throughout the delivery hospitalization, 26.5% of women met World Health Organization criteria for mild COVID-19, 26.1% for severe, and 5% for critical. Cesarean birth was the mode of delivery for 52.4% of women with severe and 91.7% with critical COVID-19. The singleton preterm birth rate was 14.6%. Admission to the intensive care unit was reported for 17 women (7.1%), and nine (3.7%) were intubated during their delivery hospitalization. There were no maternal deaths. Body mass index (BMI) 30 or higher was associated with COVID-19 severity (P=.001). Nearly all newborns tested negative for SARS-CoV-2 infection immediately after birth (97.5%). Conclusion During the first month of the SARS-CoV-2 outbreak in New York City and with evolving testing criteria, most women with laboratory-confirmed infection admitted for delivery did not have symptoms of COVID-19. Almost one third of women who were asymptomatic on admission became symptomatic during their delivery hospitalization. Obesity was associated with COVID-19 severity. Disease severity was associated with higher rates of cesarean and preterm birth.
- Published
- 2020
47. Management of multiple gestations
- Author
-
Noelle Breslin and Mary E. D'Alton
- Subjects
medicine.medical_specialty ,Referral ,Reproductive technology ,Multiple Gestation ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Humans ,Medicine ,030212 general & internal medicine ,Referral and Consultation ,Preterm delivery ,030219 obstetrics & reproductive medicine ,business.industry ,Obstetrics ,Incidence (epidemiology) ,Obstetrics and Gynecology ,Prenatal Care ,General Medicine ,Delivery, Obstetric ,Gestation ,Female ,Pregnancy, Multiple ,Level of care ,business ,Fetal medicine - Abstract
Multiple gestations are commonly encountered in both high-risk and low-risk pregnancies and, since the advent of assisted reproductive technologies in the 1980s, the numbers of multiple gestations have grown rapidly. Thus, an understanding of both the maternal and fetal risks associated with multiple gestations should be central to all obstetric practice. The ability to foresee issues and the know how to respond to the complications that develop are central to the correct management of these pregnant women. For some, appropriate management may include referral to a specialist maternal and fetal medicine physician or, in some cases, to a specialist fetal center. The present review provides a comprehensive and simplified overview of multiple gestations, including incidence, diagnosis, genetic considerations, complications (both general and specific to multiple gestation subtypes), and delivery management. It is essential that providers recognize the high-risk and specific complications that may affect a multiple gestation in order to provide the highest possible level of care for these pregnant women.
- Published
- 2020
48. Whole-Gene Sequencing of CFTR Reveals a High Prevalence of the Intronic Variant c.3874-4522A>G in Cystic Fibrosis
- Author
-
Jane C. Davies, Matthew S. Edwards, Deborah J. Morris-Rosendahl, Shibu John, Nicholas J. Simmonds, Eric W.F.W. Alton, and Melissa J. McDonnell
- Subjects
Pulmonary and Respiratory Medicine ,Genetics ,Whole genome sequencing ,Science & Technology ,IDENTIFICATION ,medicine.diagnostic_test ,business.industry ,Respiratory System ,MEDLINE ,GUIDELINES ,Critical Care and Intensive Care Medicine ,medicine.disease ,Cystic fibrosis ,DNA sequencing ,Critical Care Medicine ,General & Internal Medicine ,Genetic variation ,Medicine ,Identification (biology) ,business ,Life Sciences & Biomedicine ,11 Medical and Health Sciences ,Cohort study ,Genetic testing - Published
- 2020
49. Cannabinoids for Pain Control During Medical Abortion
- Author
-
Paula H. Bednarek, Kathleen Beardsworth, Alison Edelman, Alyssa Covelli Colwill, Jeffrey T. Jensen, Katie Alton, Lisa L. Bayer, and Bharti Garg
- Subjects
Adult ,Nausea ,medicine.medical_treatment ,Pain ,Ibuprofen ,Placebo ,law.invention ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Randomized controlled trial ,Pregnancy ,Interquartile range ,law ,medicine ,Humans ,Pain Management ,Dronabinol ,030212 general & internal medicine ,Misoprostol ,030219 obstetrics & reproductive medicine ,business.industry ,Obstetrics and Gynecology ,Abortion, Induced ,Analgesics, Non-Narcotic ,Medical abortion ,Clinical trial ,Anesthesia ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
Objective To evaluate whether prophylactic dronabinol, a synthetic tetrahydrocannabinol, reduces pain during medical abortion. Methods We conducted a randomized, double-blind, placebo-controlled trial of women undergoing medical abortion with mifepristone and misoprostol up through 70 days of gestation. All participants received 800 mg of ibuprofen and were randomized to either 5 mg of oral dronabinol or a placebo 30 minutes before misoprostol administration. Participants used a text messaging service to report pain on a numeric rating scale from 0 to 10 (0=no pain, 10=worst pain). The primary outcome was maximum pain experienced during the 24 hours after misoprostol administration. Secondary outcomes were pain scores at 0, 6, and 24 hours after misoprostol administration; maximum anxiety and nausea scores; use of additional pain medication; reported side effects; and satisfaction (yes or no). We needed 68 participants (34 per group) to have 80% power to detect a 2-point difference in maximum pain on a numeric rating scale. Results From November 2018 to May 2019, we randomized 70 women (dronabinol=35, placebo=35). Participants in the study arms had comparable baseline characteristics. We found no difference between groups in the median maximum pain score reported (dronabinol 7 [interquartile range 6-8], placebo 7 [interquartile range 5-8], P=.82) or median pain scores at any timepoint. Groups were also no different in mean maximum anxiety (dronabinol 3.33 [SD 3.06], placebo 3.23 [SD 2.53], P=.88) or nausea scores (dronabinol 2.21 [SD 2.32], placebo 2.72 [SD 2.64], P=.41). Most women were satisfied with their pain management (76% dronabinol, 82% placebo, P=.51). Conclusion Dronabinol does not reduce the maximum level of pain experienced by women undergoing medical abortion. Clinical trial registration ClinicalTrials.gov, NCT03604341.
- Published
- 2020
50. Telehealth for High-Risk Pregnancies in the Setting of the COVID-19 Pandemic
- Author
-
Laurence E. Ring, Noelia Zork, Hope S. Yates, Anita LaSala, Dena Goffman, Jennifer Haythe, Eliza C. Miller, Erica Spiegel, Leslie Moroz, Nigel Madden, Mary E. D'Alton, Ukachi N. Emeruwa, Catherine Monk, Cynthia Gyamfi-Bannerman, Jean Ju Sheen, Karin Fuchs, Aleha Aziz, Samsiya Ona, Caitlin Baptiste, Janice Aubey, Lynn L. Simpson, Russell S. Miller, and Alexander M. Friedman
- Subjects
Gestational hypertension ,medicine.medical_specialty ,Telemedicine ,telehealth ,Pregnancy, High-Risk ,Genetic counseling ,Pneumonia, Viral ,coronavirus ,Genetic Counseling ,Telehealth ,Prenatal care ,Obstetric anesthesia ,Health Services Accessibility ,Betacoronavirus ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Prenatal Diagnosis ,Obstetrics and Gynaecology ,medicine ,Humans ,Pediatrics, Perinatology, and Child Health ,Pandemics ,Infection Control ,030219 obstetrics & reproductive medicine ,SARS-CoV-2 ,business.industry ,Remote Consultation ,COVID-19 ,Obstetrics and Gynecology ,Prenatal Care ,medicine.disease ,Pregnancy Complications ,Gestational diabetes ,Pediatrics, Perinatology and Child Health ,Emergency medicine ,Original Article ,Female ,New York City ,Coronavirus Infections ,business - Abstract
As New York City became an international epicenter of the novel coronavirus disease 2019 (COVID-19) pandemic, telehealth was rapidly integrated into prenatal care at Columbia University Irving Medical Center, an academic hospital system in Manhattan. Goals of implementation were to consolidate in-person prenatal screening, surveillance, and examinations into fewer in-person visits while maintaining patient access to ongoing antenatal care and subspecialty consultations via telehealth virtual visits. The rationale for this change was to minimize patient travel and thus risk for COVID-19 exposure. Because a large portion of obstetric patients had underlying medical or fetal conditions placing them at increased risk for adverse outcomes, prenatal care telehealth regimens were tailored for increased surveillance and/or counseling. Based on the incorporation of telehealth into prenatal care for high-risk patients, specific recommendations are made for the following conditions, clinical scenarios, and services: (1) hypertensive disorders of pregnancy including preeclampsia, gestational hypertension, and chronic hypertension; (2) pregestational and gestational diabetes mellitus; (3) maternal cardiovascular disease; (4) maternal neurologic conditions; (5) history of preterm birth and poor obstetrical history including prior stillbirth; (6) fetal conditions such as intrauterine growth restriction, congenital anomalies, and multiple gestations including monochorionic placentation; (7) genetic counseling; (8) mental health services; (9) obstetric anesthesia consultations; and (10) postpartum care. While telehealth virtual visits do not fully replace in-person encounters during prenatal care, they do offer a means of reducing potential patient and provider exposure to COVID-19 while providing consolidated in-person testing and services. KEY POINTS: · Telehealth for prenatal care is feasible.. · Telehealth may reduce coronavirus exposure during prenatal care.. · Telehealth should be tailored for high risk prenatal patients..
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.